

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names: List 67

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in *Cumulative List No. 14, 2011* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES: Liste 67

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.


On trouvera d'autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la *Liste récapitulative No. 14, 2011* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS: Lista 67

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en *Cumulative List No. 14, 2011* (disponible sólo en CD-ROM).


Latin, English, French, Spanish: Recommended INN	Chemical name or description; Molecular formula; Graphic formula
DCI Recommandée	Nom chimique ou description; Formule brute; Formule développée
DCI Recomendada	Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
<b>abexinostat</b> abexinostat	3-[(dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
abexinostat	3-[(diméthylamino)méthyl]-N-{2-[4-(hydroxycarbamoyl)phénoxy]éthyl}-1-benzofurane-2-carboxamide
abexinostat	3-[(dimetilamino)metil]-N-{2-[4-(hidroxicarbamoil)fenoxi]etil}-1-benzofuran-2-carboxamida
	C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>5</sub>
	
<b>amilomotidum #</b> amilomotide	virus like particle of bacteriophage Q-beta coat protein that is coupled to multiple copies of human beta-amyloid1-6 peptide fragment; reaction products of bacteriophage Q-beta coat protein with human beta-amyloid protein-(1-6)-peptidylglycylglycyl-L-cysteine and 3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-N-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-6-oxohexyl}propanamide
amilomotide	pseudo-particule virale de la capside du phage Q-bêta couplée à plusieurs copies du fragment 1-6 de la protéine bêta-amyloïde humaine; produit obtenu par réaction de la protéine de capside du phage Q-bêta avec la protéine bêta-amyloïde humaine-(1-6)peptidylglycylglycyl-L-cystéine et le 3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-N-{6-[(2,5-dioxopyrrolidin-1-yl)oxy]-6-oxohexyl}propanamide
amilomotida	pseudo-partícula viral de cápsida del fago Q-beta acoplada a múltiples copias del fragmento 1-6 de la proteína beta-amiloide humana; producto obtenido por reacción de la proteína de cápsida del fago Q-beta con la proteína beta-amiloide humana-(1-6)peptidilglicilglicil-L-cisteína y el 3-(2,5-dioxo-2,5-dihidro-1H-pirrol-1-il)-N-{6-[(2,5-dioxopirrolidin-1-il)oxi]-6-oxohexil}propanamida

Heavy chain / Chaîne lourde / Cadena pesada

AKLETVTGLGN	IGKDGKQKTLV	LNPRGVNPTN	GVASLSQAGA	VPAL EKRVTV	50
SVSQPSRNRK	NYKVQVKIQN	PLACTANGSC	DPSVTRQAYA	DVTFSFTQYS	100
TDEERAFVRT	ELAALLASPL	LIDAIDQLNP	AY		132

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro  
74-80

Modified residues / Résidus modifiés / Residuos modificados



**anivamersenum**  
anivamersen

2'-O-methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidine

anivamersen

2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthylcytidine

anivamersén

[illegible]
$$\text{C}_{157}\text{H}_{208}\text{N}_{56}\text{O}_{103}\text{P}_{14}$$

(3'-5')-mC-mG-mC-mG-mG-mU-mA-mU-mA-mG-mU-mC-mC-mA-mC

**asunaprevirum**

asunaprevir


*tert*-butyl {(2*S*)-1-[(2*S*,4*R*)-4-({7-chloro-4-methoxyisoquinolin-1-yl}oxy)-2-({(1*R*,2*S*)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl)carbamoyl}pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl}carbamate

asunaprévir

(2*S*)-1-[(2*S*,4*R*)-4-({7-chloro-4-méthoxyisoquinolin-1-yl}oxy)-2-({(1*R*,2*S*)-1-[(cyclopropanesulfonyl)carbamoyl]-2-éthénylcyclopropyl)carbamoyl}pyrrolidin-1-yl]-3,3-diméthyl-1-oxobutan-2-yl}carbamate de *tert*-butyle

asunaprevir

{(2*S*)-1-[(2*S*,4*R*)-4-({7-cloro-4-metoxiisoquinolin-1-il}oxi)-2-({(1*R*,2*S*)-1-[(ciclopropanosulfonyl)carbamoi]-2-etenilciclopropil}carbamoi)pirrolidin-1-il]-3,3-dimetil-1-oxobutan-2-il}carbamato de *terc*-butilo

C<sub>35</sub>H<sub>46</sub>ClN<sub>5</sub>O<sub>9</sub>S**atecegatranum metoxilum**

atecegatran metoxil


(2*S*)-1-[(2*R*)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]-*N*-({4-[(*Z*)-*N*'-methoxycarbamimidoyl]phenyl}methyl)azetidine-2-carboxamide

atécégatran métoxil

(2*S*)-1-[(2*R*)-2-[3-chloro-5-(difluorométhoxy)phényl]-2-hydroxyacétyl]-*N*-({4-[(*Z*)-*N*'-méthoxycarbamimidoyl]phényl}méthyl)azétidine-2-carboxamide

atecegatrán metoxilo

(2*S*)-1-[(2*R*)-2-[3-cloro-5-(difluorometoxi)fenil]-2-hidroxiacetil]-*N*-({4-[(*Z*)-*N*'-metoxicarbamidoil]fenil}metil)azetidina-2-carboxamida

C<sub>22</sub>H<sub>23</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>5</sub>

**avagacestatum**


avagacestat

(2*R*)-2-(4-chloro-*N*-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl}benzenesulfonamido)-5,5,5-trifluoropentanamide

avagacestat

(2*R*)-2-(4-chloro-*N*-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phényl]méthyl}benzenesulfonamido)-5,5,5-trifluoropentanamide

avagacestat

(2*R*)-2-(4-cloro-*N*-{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)fenil]metil}bencenosulfonamido)-5,5,5-trifluoropentanamidaC<sub>20</sub>H<sub>17</sub>ClF<sub>4</sub>N<sub>4</sub>O<sub>4</sub>S**besifovirum**


besifovir

[({1-[(2-amino-9*H*-purin-9-yl)methyl]cyclopropyl}oxy)methyl]phosphonic acid

bésifovir

acide [({1-[(2-amino-9*H*-purin-9-yl)méthyl]cyclopropyl}oxy)méthyl]phosphonique

besifovir

ácido [({1-[(2-amino-9*H*-purin-9-il)metil]ciclopropil}oxi)metil]fosfónicoC<sub>10</sub>H<sub>14</sub>N<sub>5</sub>O<sub>4</sub>P**bitopertinum**


bitopertin

{4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}[5-(methanesulfonyl)-2-[(2*S*)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]methanone

bitopertine

{4-[3-fluoro-5-(trifluorométhyl)pyridin-2-yl]pipérazin-1-yl}[5-(méthanesulfonyl)-2-[(2*S*)-1,1,1-trifluoropropan-2-yl]oxy}phényl]méthanone

bitopertina

{4-[3-fluoro-5-(trifluorometil)piridin-2-il]piperazin-1-il}[5-(metanosulfonil)-2-[(2*S*)-1,1,1-trifluoropropan-2-il]oxy}fenil]metanonaC<sub>21</sub>H<sub>20</sub>F<sub>7</sub>N<sub>3</sub>O<sub>4</sub>S

**blosozumabum #**

blosozumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* SOST (sclerostin)], humanized monoclonal antibody;  
gamma4 heavy chain (1-444) [humanized VH (*Homo sapiens*IGHV1-24\*01 (85.70%) -(IGHD)-IGHJ4\*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG4\*01 hinge S10>P (226), CH3 K120>del (119-444)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-13\*02 (84.00%) -IGKJ1\*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; (224-224'':227-227'')-bisdisulfide dimer

blosozumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* SOST (sclérostine)], anticorps monoclonal humanisé;  
chaîne lourde gamma4 (1-444) [VH humanisé (*Homo sapiens*IGHV1-24\*01 (85.70%) -(IGHD)-IGHJ4\*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG4\*01 charnière S10>P (226), CH3 K120>del (119-444)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13\*02 (84.00%) -IGKJ1\*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure

blosozumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* SOST (esclerostina)], anticuerpo monoclonal humanizado;  
cadena pesada gamma4 (1-444) [VH humanizada (*Homo sapiens*IGHV1-24\*01 (85.70%) -(IGHD)-IGHJ4\*01 L123>T (113)) [8.8.11] (1-118) -*Homo sapiens* IGHG4\*01 bisagra S10>P (226), CH3 K120>del (119-444)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-13\*02 (84.00%) -IGKJ1\*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGASVKV	SCRKVS	GFPIK	DTFQHWVRQA	PGKGLEWMGW	50
SDPEIGDTEY	ASKFQGRVTM	TEDTSTD	TAY	MELSSLRSED	TAVYYCATGD	100
TTYKFDFWQ	GTTVTVSSAS	TKGPSV	FPLA	PCSRSTSEST	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGKTKYT	200	
CNVDHKKPSNT	KVDKRVESKY	GPCCP	PCPAP	EFLGGPSVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVDVSQEDPE	VQFNWYVDGV	EVHNAKTKPR	EEQFNSTYRV	300	
VSVLTVLHQD	WLNGKEYKCK	VSNKGLPSSI	EKTISKAKGQ	PREPQVYTL	350	
PSQEEMTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNGQFENNYK	TTTPVLDSDG	400	
SFFLYSRLTV	DKSRWQEGNV	FSCSVMEAL	HNHYTQKSLS	LSLG	444	

## Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASVGDRV	ITCKASQDVH	TAVAWYQQKP	GKAPKLLIYW	50	
ASTRWITGVPS	RFGSGSGTD	FTLTIS	SLQP	EDFATYYCQQ	YSDYPWTFGG	100
GTKVEIKRTV	AAPSVFI	PPP	SDEQLKSGTA	SVVCLLN	NFY	150
DNALQSGNSQ	ESVTEQDSKD	STYSL	SSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214	

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	145-201	259-319	365-423
	22"-96"	145"-201"	259"-319"	365"-423"
Intra-L	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L	132-214'	132"-214'"		
Inter-H-H	224-224"	227-227"		

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

295, 295"

**brodalumabum #**

brodalumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* IL17RA (interleukin 17 receptor A, CD217)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-442) [*Homo sapiens* VH (IGHV1-18\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2\*01 (117-442)], (130-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-15\*01 (93.70%) -IGKJ4\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; (218-218":219-219":222-222":225-225")-tetrakisdisulfide dimer

brodalumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* IL17RA (récepteur A de l'interleukine 17, CD217)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-442) [*Homo sapiens* VH (IGHV1-18\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2\*01 (117-442)], (130-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-15\*01 (93.70%) -IGKJ4\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimère (218-218":219-219":222-222":225-225")-tétrakisdisulfure

brodalumab

inmunoglobulina G2-kappa, anti-[IL17RA (receptor A de la interleukina 17 de *Homo sapiens*, CD217)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma2 (1-442) [*Homo sapiens* VH (IGHV1-18\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2\*01 (117-442)], (130-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-15\*01 (93.70%) -IGKJ4\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dímero (218-218":219-219":222-222":225-225")-tetrakisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	RYGISWVRQA	PGQGLEWMGW	50
ISTYSGNTNY	AQKLQGRVTM	TTDTSTSTAY	MELRSLRSD	TAVYYCARRQ	100
LYFDYWGGT	LVTVSSASTK	GPSVFPLAPC	SRSTSESTAA	LGCLVKDYFP	150
EPVTVSWNSG	ALTSQGVHTF	AVLQSSGLYS	LSSVVTVPSS	NFGDTYTCN	200
VDHKPSNTKV	DKTVERKCCV	ECPPCPAPPV	AGPSVFLFPP	KPKDTLMISR	250
TPEVTCVVVD	VSHEDPEVQF	NWYVDGVEVH	NAKTKPREEQ	FNSTFRVSV	300
LTVVHQQDLN	GKEYKCKVSN	KGLPAPIEKT	ISKTKGQPRE	PQVYTLPPSR	350
EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QFENNYKTTT	PMLDSGGSFF	400
LYSKLTVDKS	RWQQGNVFSC	SVMHEALHNH	YTQKSLSLSP	GK	442

## Light chain / Chaîne légère / Cadena ligera

EIVMTQSPAT	LSVSPGERAT	LSCRASQSVS	SNLAWFQQKP	GQAPRPLIYD	50
ASTRATGVPA	RFSGSGSGTD	FTLTISSLQS	EDFAVYYCQQ	YDNWPLTFGG	100
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQNKV	150
DNALQSGNSQ	ESVTEQDSKD	STYSLSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	143-199	256-316	362-420
	22"-96"	143"-199"	256"-316"	362"-420"

Intra-L	23'-88'	134'-194'
	23"-88"	134"-194"

Inter-H-L	130-214'	130"-214"
-----------	----------	-----------

Inter-H-H	218-218"	219-219"	222-222"	225-225"
-----------	----------	----------	----------	----------

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
292, 292"

**cabozantinibum**

cabozantinib



*N*-(4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

cabozantinib

*N*-(4-[(6,7-diméthoxyquinoléin-4-yl)oxy]phényl)-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

cabozantinib

*N*-(4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil)-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida



**calaspargasum pegolum #**  
calaspargase pegol


pegylated *Escherichia coli* asparaginase;  
[27-alanine,64-aspartic acid,252-threonine,263-asparagine]-  
L-asparaginase 2 (EC 3.5.1.1, L-asparagine amidohydrolase II)  
*Escherichia coli* (strain K12) tetramer  $\alpha_4$ , carbamates with  $\alpha$ -carboxy-  
 $\omega$ -methoxypoly(oxyethylene)

calaspargase pégol

asparaginase d'*Escherichia coli* pégylée;  
carbamates entre le tétramère  $\alpha_4$  de [27-alanine,64-acide  
aspartique,252-thréonine,263-asparagine]-L-asparaginase 2 (EC  
3.5.1.1, L-asparagine amidohydrolase II) d'*Escherichia coli* (souche  
K12) et le  $\alpha$ -carboxy- $\omega$ -méthoxypoly(oxyéthylène)

calaspargasa pegol

asparaginasa de *Escherichia coli* pegilada;  
carbamatos entre el tetrámero  $\alpha_4$  de [27-alanina,64-ácido  
aspártico,252-treonina,263-asparagina]-L-asparaginasa 2 (EC  
3.5.1.1, L-asparagina amidohidrolasa II) de *Escherichia coli* (cepa  
K12) y el  $\alpha$ -carboxi- $\omega$ -metoxipoli(oxietileno)



Monomer / Monomère / Monómero

```


LPNITILATG GTIAGGGDSA TKSNYTAGKV GVENLVNAV PQLKDIANVKG 50
EQVVNIGSQD MNDDVWLT LA KKINTDCDKT DGFVITHGTD TMEETAYFLD 100
LTVKCDKPVV MVGAMRPSTS MSADGPFNLY NAVVTAADKA SANRGVLVVM 150
NDTVLDGRDV TKTNTDVTAT FKSVDNYGPLG YIHNGKIDYQ RTPARKHTSD 200
TPFDVSKLNE LFKVGIVVNY ANASDLPAKA LVDAGYDGIV SAGVGNGNLY 250
KTVFDTLATA AKNGTAVVRS SRVPTGATTQ DAEVDDAKYG FVASGTLPNQ 300
KARVLLQLAL TQTKDPQQIQ QIFNQY 326

```

approximately 9 residues are pegylated out of 23 (1 L and 22 K)

environ 9 résidus sur 23 (1 L et 22 K) sont pégylés

aproximadamente están pegilados 9 restos de 23 (1L y 22K)



Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
77-105 77'-105' 77'''-105''' 77''''-105''''



**cantuzumabum ravtansinum #**

cantuzumab ravtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242)], humanized monoclonal antibody conjugated to maytansinoid DM4; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV7-4-1\*02 (76.50%) -(IGHD)-IGHJ2\*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens*IGHG1\*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-28\*01 (82.00%) -IGKJ3\*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [*N*<sup>2</sup>-deacetyl-*N*<sup>2</sup>-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [*N*-succinimidyl 4-(2-pyridyldithio)butanoate]

For the *ravtansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*"

cantuzumab ravtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* glycané sialylé de MUC1, associé à des tumeurs (CA242, antigène du cancer 242)], anticorps monoclonal humanisé conjugué au maytansinoïde DM4; chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV7-4-1\*02 (76.50%) -(IGHD)-IGHJ2\*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens*IGHG1\*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2-28\*01 (82.00%) -IGKJ3\*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM4 [*N*<sup>2</sup>-déacétyl-*N*<sup>2</sup>-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de *N*-succinimidyle]

Pour la partie *ravtansine*, veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

cantuzumab ravtansina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* glicano sialilo de MUC1, asociado al tumor (CA242, antígeno del cancer 242)] anticuerpo monoclonal humanizado conjugado con el maitansinoide DM4;

cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens*IGHV7-4-1\*02 (76.50%) -(IGHD)-IGHJ2\*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens*IGHG1\*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens*IGKV2-28\*01 (82.00%) -IGKJ3\*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, en 3-4 grupos lisil por término medio, con el maitansinoide DM4 [*N*<sup>2</sup>-desacetil-*N*<sup>2</sup>-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el conector SPDB reducible [*N*-4-(2-piridilditio)butanoato de succinimidilo]

Para la fracción *ravtansina*, se ruega referirse al documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGETVKI SKASDYTFY YGGMNWKQA PGQGLKWMGW 50  
 IDTTTGEPTY AQKFQGRIF SLETSASTAY LQIKSLKSED TATYFCARRG 100  
 PYNWYFDVWG QGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150  
 YFPEPVTVSW NSGALTSGVH TFPVQLQSSG LYSLSVVTV PSSSLGTQTY 200  
 ICNVNHPKSN TKVDKKVEPK SCDKTHTCP CPAPPELLGGP SVFLFPPKPK 250  
 DTLMISRTPV VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300  
 TYRVVSVLTV LQDQWLNKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350  
 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400  
 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

## Light chain / Chaîne légère / Cadena ligera

DIVMTQSPLS VPVTPGEPVS ISCRSSKSL L HSGNTYLYW FLQRPQGSFQ 50  
 LLIYRMSNLV SGVPDRFSGS GSGTFTLR SRVEAEDGVV YYCLOHLEYP 100  
 FTFGPGTKLE LKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150  
 VQWKVDNALQ SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE 200  
 VTHQGLSSPV TKSFNREGC 219

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427  
 22"-96" 146"-202" 263"-323" 369"-427"

Intra-L 23'-93' 139'-199'  
 23'''-93''' 139'''-199'''

Inter-H-L 222-219' 222"-219"  
 Inter-H-H 228-228" 231-231"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

**ceftolozanum**

ceftolozane

(6*R*,7*R*)-3-[(5-amino-4-[(2-aminoethyl)carbamoyl]amino)-1-methyl-1*H*-pyrazol-2-ium-2-yl)methyl]-7-[(2*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[[[(2-carboxypropan-2-yl)oxy]imino]acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate


ceftolozane

(6*R*,7*R*)-3-[(5-amino-4-[(2-aminoéthyl)carbamoyl]amino)-1-méthyl-1*H*-pyrazol-2-ium-2-yl)méthyl]-7-[(2*Z*)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-[[[(2-carboxypropan-2-yl)oxy]imino]acétamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate

ceftolozano

(6*R*,7*R*)-3-[(5-amino-4-[(2-aminoetil)carbamoi]amino)-1-metil-1*H*-pirazol-2-io-2-il)metil]-7-[(2*Z*)-2-(5-amino-1,2,4-tiadiazol-3-il)-2-[[[(2-carboxipropan-2-il)oxo]imino]acetamido]-8-oxo-5-tia-1-azabiciiclo[4.2.0]oct-2-eno-2-carboxilato

C<sub>23</sub>H<sub>30</sub>N<sub>12</sub>O<sub>8</sub>S<sub>2</sub>

**cenderitidum**

cenderitide

natriuretic peptide receptor type B (NPR-B) agonist;  
 human C-type natriuretic peptide-(32-53)-peptide (CNP-22) fusion  
 protein with eastern green mamba (*Dendroaspis angusticeps*)  
 natriuretic peptide-(24-38)-peptide

cendéritide	agoniste du récepteur du peptide natriurétique de type B; peptide natriurétique de type-C humain-(32-53)-peptide (CNP-22) protéine de fusion avec le peptide natriurétique de <i>Dendroaspis angusticeps</i> (mamba vert)-(24-38)-peptide
cenderitida	agonista del receptor del péptido natriurético de tipo B; péptido natriurético de tipo-C humano-(32-53)-péptido (CNP-22) proteína de fusión con el péptido natriurético de <i>Dendroaspis angusticeps</i> (mamba vert)-(24-38)-péptido
	$C_{158}H_{263}N_{49}O_{50}S_3$
	GLSKGCFGLK LDRIGSMSGL GCPSLRDRP NAPSTA 37
	Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro 6-22
<b>cepeginterferonum alfa-2b #</b> cepeginterferon alfa-2b	pegylated human interferon alpha-2b; $N^{2,1}$ -{4-[ω-methoxypoly(oxyethylene)]butyl}-human interferon alpha-2b
cépeginterféron alfa-2b	interféron alpha-2b humain pégylé; $N^{2,1}$ -{4-[ω-méthoxypoly(oxyéthylène)]butyl}-interféron alpha-2b humain
cepeginterferón alfa-2b	interferón alfa-2b humano pegilado; $N^{2,1}$ -{4-[ω-metoxipoli(oxietileno)]butil}-interferón alfa-2b humano
	$C_{865}H_{1359}N_{229}O_{256}S_9 [C_2H_4O]_n$
	CDLPQTHSLG SRRTLMLLAQ MRRISLFSCL KDRHDFGFPO EEFNGQFQKA 50 ETIPVLHEMI QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI 100 QGVGVTEPL MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS 150 FSLSTNLQES LRSKE 165
	Disulfide bridges location / Positions des ponts disulfure / Posiciones de los puentes disulfuro 1-98 29-138
	Modified residue / Résidu modifié / Residuo modificado
<b>conberceptum #</b> conbercept	fusion protein for immune applications (FPIA) comprising <i>Homo sapiens</i> FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR1, vascular permeability factor receptor, tyrosine-protein kinase FRT) fragment, fused with <i>Homo sapiens</i> KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, protein-tyrosine kinase receptor FLK1, CD309) fragment, fused with <i>Homo sapiens</i> immunoglobulin G1 Fc fragment; FLT1, 132-232 precursor fragment (1-101) -KDR, 227-421 precursor fragment (102-296) -glycyl-prolyl-glycyl (297-299) -gamma1 chain H-CH2-CH3 fragment (300-526) [ <i>Homo sapiens</i> IGHG1*03 hinge 6-15 P13>L (307) (300-309), CH2 (310-419), CH3-CH-S (420-526)]; (305-305':308-308')-bisdisulfide dimer

conbercept protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'*Homo sapiens* FLT1 (tyrosine kinase 1 apparentée au fms, récepteur 1 du facteur de croissance de l'endothélium vasculaire, VEGFR1, récepteur du facteur de perméabilité vasculaire, tyrosine-protéine kinase FRT), fusionné à un fragment d'*Homo sapiens* KDR (récepteur à domaine kinase, récepteur 2 du facteur de croissance de l'endothélium vasculaire, VEGFR2, récepteur tyrosine-protéine kinase FLK1, CD309), fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1; FLT1, fragment 132-232 du précurseur (1-101) -KDR, fragment 227-421 du précurseur (102-296) - glycyL-prolyl-glycyl (297-299) - fragment H-CH2-CH3 de la chaîne gamma1 (300-526) [*Homo sapiens*IGHG1\*03 charnière 6-15 P13>L (307) (300-309), CH2 (310-419), CH3-CH-S (420-526)]; dimère (305-305':308-308')-bisdisulfure

conbercept proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de FLT1 de *Homo sapiens* (tirosina kinasa 1 relacionada con fms, receptor 1 del factor de crecimiento del endotelio vascular, VEGFR1, receptor del factor de permeabilidad vascular, tirosina-protein kinasa FRT), fusionada a un fragmento de KDR de *Homo sapiens* (receptor con dominio kinasa, receptor 2 del factor de crecimiento del endotelio vascular, VEGFR2, receptor tirosina-protein kinasa FLK1, CD309), fusionado al fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*; FLT1, fragmento 132-232 de precursor (1-101) -KDR, fragmento 227-421 del precursor (102-296) - glicil-prolil-glicil (297-299) - fragmento H-CH2-CH3 de la cadena gamma1 (300-526) [*Homo sapiens*IGHG1\*03 bisagra 6-15 P13>L (307) (300-309), CH2 (310-419), CH3-CH-S (420-526)]; dímero (305-305':308-308')-bisdisulfuro

## Fused chain / chaîne fusionnée / cadena fusionada

```
GRPFVEMYSE IPEIIHMTG RELVPCRV T SPNITVTLLK FPLDTLIPDG 50
KRIIWDSRKG FIISNATYKE IGLLTCEATV NGHLYKTNYL THRQNTIID 100
VVLSPSHGIE LSVGEKLVN CTARTELVG IDFNWEYPSS KHQHKLVNR 150
DLKTQSGSEM KFLSTLTID GVTRSDQGLY TCAASSGLMT KKNSTFVRVH 200
EKPFVAFSGS MESLVEATVG ERVRIPAKYL GYPPEIKWY KNGIPLESNH 250
TIKAGHVLT I MEVSRDTGN YTVILTNPIS KEKQSHVVS L VVYVPPGPGD 300
KTHTCPLCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP 350
EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC 400
KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN QVSLTCLVKG 450
FYPSDIAVEW ESNQGPENNY KATPPVLDSG GSFFLYSKLT VDKSRWQQGN 500
VFSCSVMHEA LHNHYTQKSL SLSPGK 526
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain 27-76 121-182 340-400 446-504

27'-76' 121'-182' 340'-400' 446'-504'

Inter-chains 305-305' 308-308'



## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

376, 376'

**crenezumabum #**  
crenezumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* amyloid beta (Aβeta) peptides Aβ42 and Aβ40]], humanized monoclonal antibody; gamma4 heavy chain (1-438) [humanized VH (*Homo sapiens*IGHV3-23\*04 (89.70%) -(IGHD)-IGHJ4\*01 L123>T (107) [8.8.5] (1-112) -*Homo sapiens*IGHG4\*01 hinge S10>P (220) (113-438)], (126-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2D-29\*02 (86.00%) -IGKJ1\*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; (218-218'':221-221'')-bisdisulfide dimer

crénezumab	immunoglobuline G4-kappa, anti-[ <i>Homo sapiens</i> peptides <i>bé</i> ta-amyloïdes ( <i>Abé</i> ta) Aβ42 et Aβ40]], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-438) [VH humanisé ( <i>Homo sapiens</i> IGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5] (1-112) - <i>Homo sapiens</i> IGHG4*01 charnière S10>P (220) (113-438)], (126-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé ( <i>Homo sapiens</i> IGKV2D-29*02 (86.00%) -IGKJ1*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dimère (218-218":221-221")-bisdisulfure																																																																																																																		
crenezumab	inmunoglobulina G4-kappa, anti-[péptidos <i>beta-amiloïdes</i> ( <i>Abeta</i> ) Aβ42 y Aβ40 de <i>Homo sapiens</i> ]], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-438) [VH humanizada ( <i>Homo sapiens</i> IGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5] (1-112) - <i>Homo sapiens</i> IGHG4*01 bisagra S10>P (220) (113-438)], (126-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada ( <i>Homo sapiens</i> IGKV2D-29*02 (86.00%) -IGKJ1*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dímero (218-218":221-221")-bisdisulfuro																																																																																																																		
	<div>Heavy chain / Chaîne lourde / Cadena pesada</div> <table><tr><td>EVQLVESGGG</td><td>LVQPGGSLRL</td><td>SCAASGFTFS</td><td>SYGMSWVRQA</td><td>PGKGLLELVAS</td><td>50</td></tr><tr><td>INSNGGSTYY</td><td>PDSVKGRFTI</td><td>SRDNAKNSLY</td><td>LQMNSLRAED</td><td>TAVYYCASGD</td><td>100</td></tr><tr><td>YWGGQTTVTV</td><td>SSASTKGPSV</td><td>FPLAPCSRST</td><td>SESTAALGCL</td><td>VKDYFPEPVT</td><td>150</td></tr><tr><td>VSWNSGALTS</td><td>GVHTFPAVLQ</td><td>SSGLYSLSSV</td><td>VTVPSSSLGT</td><td>KTYTCNVDPHK</td><td>200</td></tr><tr><td>PSNTKVDKRV</td><td>ESKYGPCCPP</td><td>CPAPEFLGGP</td><td>SVFLFPKPK</td><td>DTLMISRTP</td><td>250</td></tr><tr><td>VTCVVVDVQ</td><td>EDPEVQFNWY</td><td>VDGVEVHNAK</td><td>TKPREEQFNS</td><td>TYRVVSVLTV</td><td>300</td></tr><tr><td>LHQDWLNGKE</td><td>YCKVSNKGL</td><td>PSSIEKTISK</td><td>AKGQPREPQV</td><td>YTLPPSQEEM</td><td>350</td></tr><tr><td>TKNQVSLTCL</td><td>VKGFPYSDIA</td><td>VEWESNGQPE</td><td>NNYKTTTPVL</td><td>DSGDSFFLYS</td><td>400</td></tr><tr><td>RLTVDKSRWQ</td><td>EGNVFSCSVM</td><td>HEALHNHYTQ</td><td>KSLSLSLG</td><td></td><td>438</td></tr></table> <div>Light chain / Chaîne légère / Cadena ligera</div> <table><tr><td>DIVMTQSPLS</td><td>LPVTPGEPAS</td><td>ISCRSSQSLV</td><td>YSNGDTYLHW</td><td>YLQKPGQSPQ</td><td>50</td></tr><tr><td>LLIYKVSNR</td><td>SGVPDRFSGS</td><td>GSCTDFTLKI</td><td>SRVEAEDVGV</td><td>YYCSQSTHVP</td><td>100</td></tr><tr><td>WTFGQGTKE</td><td>IKRTVAAPSV</td><td>FIFPPSDEQL</td><td>KSGTASVVCL</td><td>LNNFYPREAK</td><td>150</td></tr><tr><td>VQWKVDNALQ</td><td>SGNSQESVTE</td><td>QDSKDSSTYS</td><td>SSTLTLSKAD</td><td>YEKHKVYACE</td><td>200</td></tr><tr><td>VTHQGLSPV</td><td>TKSFNRGEC</td><td></td><td></td><td></td><td>219</td></tr></table> <div>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</div> <table><tr><td>Intra-H</td><td>22-96</td><td>139-195</td><td>253-313</td><td>359-417</td></tr><tr><td></td><td>22"-96"</td><td>139"-195"</td><td>253"-313"</td><td>359"-417"</td></tr><tr><td>Intra-L</td><td>23'-93'</td><td>139'-199'</td><td></td><td></td></tr><tr><td></td><td>23'''-93'''</td><td>139'''-199'''</td><td></td><td></td></tr><tr><td>Inter-H-L</td><td>126-219'</td><td>126"-219"</td><td></td><td></td></tr><tr><td>Inter-H-H</td><td>218-218"</td><td>221-221"</td><td></td><td></td></tr></table> <div>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación</div> <div>289, 289"</div>	EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	SYGMSWVRQA	PGKGLLELVAS	50	INSNGGSTYY	PDSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCASGD	100	YWGGQTTVTV	SSASTKGPSV	FPLAPCSRST	SESTAALGCL	VKDYFPEPVT	150	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	KTYTCNVDPHK	200	PSNTKVDKRV	ESKYGPCCPP	CPAPEFLGGP	SVFLFPKPK	DTLMISRTP	250	VTCVVVDVQ	EDPEVQFNWY	VDGVEVHNAK	TKPREEQFNS	TYRVVSVLTV	300	LHQDWLNGKE	YCKVSNKGL	PSSIEKTISK	AKGQPREPQV	YTLPPSQEEM	350	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTTTPVL	DSGDSFFLYS	400	RLTVDKSRWQ	EGNVFSCSVM	HEALHNHYTQ	KSLSLSLG		438	DIVMTQSPLS	LPVTPGEPAS	ISCRSSQSLV	YSNGDTYLHW	YLQKPGQSPQ	50	LLIYKVSNR	SGVPDRFSGS	GSCTDFTLKI	SRVEAEDVGV	YYCSQSTHVP	100	WTFGQGTKE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150	VQWKVDNALQ	SGNSQESVTE	QDSKDSSTYS	SSTLTLSKAD	YEKHKVYACE	200	VTHQGLSPV	TKSFNRGEC				219	Intra-H	22-96	139-195	253-313	359-417		22"-96"	139"-195"	253"-313"	359"-417"	Intra-L	23'-93'	139'-199'				23'''-93'''	139'''-199'''			Inter-H-L	126-219'	126"-219"			Inter-H-H	218-218"	221-221"		
EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	SYGMSWVRQA	PGKGLLELVAS	50																																																																																																														
INSNGGSTYY	PDSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCASGD	100																																																																																																														
YWGGQTTVTV	SSASTKGPSV	FPLAPCSRST	SESTAALGCL	VKDYFPEPVT	150																																																																																																														
VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	KTYTCNVDPHK	200																																																																																																														
PSNTKVDKRV	ESKYGPCCPP	CPAPEFLGGP	SVFLFPKPK	DTLMISRTP	250																																																																																																														
VTCVVVDVQ	EDPEVQFNWY	VDGVEVHNAK	TKPREEQFNS	TYRVVSVLTV	300																																																																																																														
LHQDWLNGKE	YCKVSNKGL	PSSIEKTISK	AKGQPREPQV	YTLPPSQEEM	350																																																																																																														
TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTTTPVL	DSGDSFFLYS	400																																																																																																														
RLTVDKSRWQ	EGNVFSCSVM	HEALHNHYTQ	KSLSLSLG		438																																																																																																														
DIVMTQSPLS	LPVTPGEPAS	ISCRSSQSLV	YSNGDTYLHW	YLQKPGQSPQ	50																																																																																																														
LLIYKVSNR	SGVPDRFSGS	GSCTDFTLKI	SRVEAEDVGV	YYCSQSTHVP	100																																																																																																														
WTFGQGTKE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150																																																																																																														
VQWKVDNALQ	SGNSQESVTE	QDSKDSSTYS	SSTLTLSKAD	YEKHKVYACE	200																																																																																																														
VTHQGLSPV	TKSFNRGEC				219																																																																																																														
Intra-H	22-96	139-195	253-313	359-417																																																																																																															
	22"-96"	139"-195"	253"-313"	359"-417"																																																																																																															
Intra-L	23'-93'	139'-199'																																																																																																																	
	23'''-93'''	139'''-199'''																																																																																																																	
Inter-H-L	126-219'	126"-219"																																																																																																																	
Inter-H-H	218-218"	221-221"																																																																																																																	
crenolanibum																																																																																																																			
crenolanib	1-(2-{5-[(3-methyloxetan-3-yl)methoxy]-1 <i>H</i> -benzimidazol-1-yl}quinolin-8-yl)piperidin-4-amine																																																																																																																		
crénolanib	1-(2-{5-[(3-méthyloxétan-3-yl)méthoxy]-1 <i>H</i> -benzimidazol-1-yl}quinoléin-8-yl)pipéridin-4-amine																																																																																																																		
crenolanib	1-(2-{5-[(3-metiloxetan-3-il)metoxi]-1 <i>H</i> -benzoimidazol-1-il}quinolin-8-il)piperidin-4-amina																																																																																																																		

**dabrafenibum**

dabrafenib



*N*-{3-[5-(2-aminopyrimidin-4-yl)-2-*tert*-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide

dabrafénib

*N*-{3-[5-(2-aminopyrimidin-4-yl)-2-*tert*-butyl-1,3-thiazol-4-yl]-2-fluorophényl}-2,6-difluorobenzènesulfonamide

dabrafenib

*N*-{3-[5-(2-aminopirimidin-4-il)-2-*terc*-butil-1,3-tiazol-4-il]-2-fluorofenil}-2,6-difluorobencenosulfonamido

**daclatasvirum**

daclatasvir



dimethyl *N,N'*-([1,1'-biphenyl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl]}[(1*S*)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate

daclatasvir

*N,N'*-([1,1'-biphényl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl]}[(1*S*)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

daclatasvir

*N,N'*-([1,1'-bifenil]-4,4'-diilbis{1*H*-imidazol-5,2-diil-[(2*S*)-pirrolidina-2,1-diil]}[(1*S*)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo



**dalanterceptum #**

dalantercept

fusion protein for immune applications (FPIA) comprising *Homo sapiens* ACVRL1 (activin A receptor type II-like 1, activin receptor-like kinase 1, ALK1, ALK-1, serine/threonine-protein kinase receptor R3, SKR3, transforming growth factor-beta superfamily receptor type I, TGF-B superfamily receptor type I, TSR-I, HHT2, ORW2) fragment, fused with *Homo sapiens* immunoglobulin G1 Fc fragment; ACVR2L1, 22-120 precursor fragment (1-99) -threonyl-triglycyl (100-103) -gamma1 chain H-CH2-CH3 fragment (104-328) [*Homo sapiens*IGHG1\*03 hinge 8-15 (104-111), CH2 L1.3>A (115), G1>A (118), A115>V (211) (112-221), CH3 S85.3>P (284) (222-328)]; (107-107':110-110')-bisdisulfide dimer

dalantercept

protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'*Homo sapiens* ACVRL1 (récepteur 1 de type II-like de l'activine A, kinase 1 apparentée au récepteur de l'activine, ALK1, ALK-1, récepteur R3 de type sérine/thréonine-protéine kinase, SKR3, récepteur de type I de la superfamille du facteur de croissance transformant bêta, récepteur de type I de la superfamille du TGF-B, TSR-I, HHT2, ORW2), fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1; ACVR2L1, fragment 22-120 du précurseur (1-99) -thréonyl-triglycyl (100-103) -fragment H-CH2-CH3 de la chaîne gamma1 (104-328) [*Homo sapiens*IGHG1\*03 charnière 8-15 (104-111), CH2 L1.3>A (115), G1>A (118), A115>V (211) (112-221), CH3 S85.3>P (284) (222-328)]; dimère (107-107':110-110')-bisdisulfure

dalantercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de ACVRL1 de *Homo sapiens* (receptor 1 de tipo II-like de la activina A, kinasa 1 relacionada con el receptor de la activina, ALK1, ALK-1, receptor R3 de tipo serina/treonina-proteinkinasa, SKR3, receptor de tipo I de la superfamilia del factor de crecimiento transformador beta, receptor de tipo I de la superfamilia del TGF-B, TSR-I, HHT2, ORW2), fusionada con el fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*; ACVR2L1, fragmento 22-120 del precursor (1-99) -treonil-triglicil (100-103) -fragmento H-CH2-CH3 de la cadena gamma1 (104-328) [*Homo sapiens*IGHG1\*03 bisagra 8-15 (104-111), CH2 L1.3>A (115), G1>A (118), A115>V (211) (112-221), CH3 S85.3>P (284) (222-328)]; dímero (107-107':110-110')-bisdisulfuro

## Fused chain / chaîne fusionnée / cadena fusionada

```
DPVKPSRGPL VTCTCESPHC KGPTCRGAWC TVVLVREEGR HPQEHRCGN 50
LHRELGRGRP TEFVNHCCD SHLCNHNVS LLEATQPPSE QPGTDGQLAT 100
GGGTHTCPPC PAPEALGAPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE 150
DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY 200
KCKVSNKALP VPIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV 250
KGFYPSDIAV EWESNGQPEN NYKTPPVLD SDGPFPLYSK LTVDKSRWQQ 300
GNVFSCSVMH EALHNNHYTQK SLSLSPGK 328
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain 13-30 15-20 25-48 56-68 69-74 142-202 248-306  
 13'-30' 15'-20' 25'-48' 56'-68' 69'-74' 142'-202' 248'-306'  
 Inter-chains 107-107' 110-110'

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

77, 178, 77', 178'

**dasolampanelum**


dasolampanel

(3*S*,4*aS*,6*S*,8*aR*)-6-[3-chloro-2-(1*H*-tetrazol-5-yl)phenoxy]-decahydroisoquinoline-3-carboxylic acid

dasolampanel

acide (3*S*,4*aS*,6*S*,8*aR*)-6-[3-chloro-2-(1*H*-tétrazol-5-yl)phénoxy]décahydroisoquinoléine-3-carboxylique

dasolampanel

ácido (3*S*,4*aS*,6*S*,8*aR*)-6-[3-cloro-2-(1*H*-tetrazol-5-il)fenoxi]-decahidroisoquinolina-3-carboxílico $C_{17}H_{20}ClN_5O_3$ **delanzomibum**


delanzomib

{(1*R*)-1-[(2*S*,3*R*)-3-hydroxy-2-(6-phenylpyridine-2-carboxamido)butanamido]-3-methylbutyl}boronic acid

délanzomib

acide {(1*R*)-1-[(2*S*,3*R*)-3-hydroxy-2-(6-phénylpyridine-2-carboxamido)butanamido]-3-méthylbutyl}boronique

delanzomib

ácido {(1*R*)-1-[(2*S*,3*R*)-3-hidroxi-2-(6-fenilpiridina-2-carboxamido)butanamido]-3-metilbutil}borónico $C_{21}H_{28}BN_3O_5$ **delcasertibum**

delcasertib

human immunodeficiency virus 1 protein Tat-(46-57)-peptide (1→1')-disulfide with L-cysteinyl-[mouse protein kinase C delta type-(8-17)-peptide]

delcasertib

protéine Tat du virus 1 de l'immunodéficience humaine-(46-57)-peptide (1→1')-disulfure avec le L-cystéinyl-(protéine kinase C type delta de souris-(8-17)-peptide)

delcasertib

proteína Tat del virus 1 de la inmunodeficiencia humana-(46-57)-péptido (1→1')-disulfuro con la L-cisteinil-[proteína kinasa C tipo delta de ratón-(8-17)-péptido]



	$C_{120}H_{199}N_{45}O_{34}S_2$
	A chain / Chaîne A / Cadena A CYGRKKRRQR RR 12
	Light chain / Chaîne légère / Cadena ligera CSFNSYELGS L 11'
	Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro 1-1'

**dolutegravirum**

dolutegravir


(4*R*,12*aS*)-*N*-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12*a*-hexahydro-2*H*-pyrido[1',2':4,5]pyrazino[2,1-*b*][1,3]oxazine-9-carboxamide

dolutégravir

(4*R*,12*aS*)-*N*-[(2,4-difluorophényl)méthyl]-7-hydroxy-4-méthyl-6,8-dioxo-3,4,6,8,12,12*a*-hexahydro-2*H*-pyrido[1',2':4,5]pyrazino[2,1-*b*][1,3]oxazine-9-carboxamide

dolutegravir

(4*R*,12*aS*)-*N*-[(2,4-difluorofenil)metil]-7-hidroxi-4-metil-6,8-dioxo-3,4,6,8,12,12*a*-hexahidro-2*H*-pirido[1',2':4,5]pirazino[2,1-*b*][1,3]oxazina-9-carboxamida

 $C_{20}H_{19}F_2N_3O_5$ **encaleretum**

encaleret


2'-{[(1*R*)-1-[(2*R*)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methyl[1,1'-biphenyl]-4-carboxylic acid

encaléret

acide 2'-{[(1*R*)-1-[(2*R*)-3-[[1-(4-chloro-3-fluorophényl)-2-méthylpropan-2-yl]amino]-2-hydroxypropoxy]éthyl]-3-méthyl[1,1'-biphényl]-4-carboxylique

encaleret

ácido 2'-{[(1*R*)-1-[(2*R*)-3-[[1-(4-cloro-3-fluorofenil)-2-metilpropan-2-yl]amino]-2-hidroxiopropoxi]etil]-3-metil[1,1'-bifenil]-4-carboxílico

 $C_{29}H_{33}ClFNO_4$ 

**epelsibanum**


epelsiban

(3*R*,6*R*)-3-(2,3-dihydro-1*H*-inden-2-yl)-1-[(1*R*)-1-(2,6-dimethylpyridin-3-yl)-2-(morpholin-4-yl)-2-oxoethyl]-6-[(2*S*)-butan-2-yl]piperazine-2,5-dione

épelsiban

(3*R*,6*R*)-3-(2,3-dihydro-1*H*-indén-2-yl)-1-[(1*R*)-1-(2,6-diméthylpyridin-3-yl)-2-(morpholin-4-yl)-2-oxoéthyl]-6-[(2*S*)-butan-2-yl]pipérazine-2,5-dione

epelsibán

(3*R*,6*R*)-3-(2,3-dihidro-1*H*-inden-2-il)-1-[(1*R*)-1-(2,6-dimetilpiridin-3-il)-2-(morfolin-4-il)-2-oxoetil]-6-[(2*S*)-butan-2-il]piperazina-2,5-dionaC<sub>30</sub>H<sub>38</sub>N<sub>4</sub>O<sub>4</sub>**etoxybamidum**


etoxybamide

4-hydroxy-*N*-(2-hydroxyethyl)butanamide

étoxybamide

4-hydroxy-*N*-(2-hydroxyéthyl)butanamide

etoxibamida

4-hidroxi-*N*-(2-hidroxietil)butanamidaC<sub>6</sub>H<sub>13</sub>NO<sub>3</sub>**evacetrapibum**

evacetrapib



(1*r*,4*r*)-4-({(5*S*)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2*H*-tetrazol-5-yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl)methyl)cyclohexane-1-carboxylic acid

évacétrapib

acide (1*r*,4*r*)-4-({(5*S*)-5-[[[3,5-bis(trifluorométhyl)phényl]méthyl](2-méthyl-2*H*-tétrazol-5-yl)amino]-7,9-diméthyl-2,3,4,5-tétrahydro-1*H*-benzazépin-1-yl)méthyl)cyclohexane-1-carboxylique

evacetrapib

ácido (1*r*,4*r*)-4-({(5*S*)-5-[[[3,5-bis(trifluorometil)fenil]metil](2-metil-2*H*-tetrazol-5-il)amino]-7,9-dimetil-2,3,4,5-tetrahidro-1*H*-1-benzazepin-1-il}metil)ciclohexano-1-carboxílico



**exeporfinii chloridum**  
exeporfinium chloride


3,3'-(21*H*,23*H*-porphyrin-5,15-diylbis[(4,1-phenylene)oxy]-*N,N,N*-trimethylpropan-1-aminium)} dichloride

chlorure d'exéporfinium

dichlorure de 3,3'-[21*H*,23*H*-porphyrin-5,15-diylbis(4,1-phénylèneoxy)]bis[*N,N,N*-triméthylpropan-1-aminium]

cloruro de exeporfinio

dicloruro de 3,3'-(21*H*,23*H*-porfirin-5,15-diilbis[(4,1-fenileno)oxi]-*N,N,N*-trimetilpropan-1-aminium)}



**fabomotizolum**  
fabomotizole



5-ethoxy-2-[[2-(morpholin-4-yl)ethyl]sulfanyl]-1*H*-benzimidazole

fabomotizole

5-éthoxy-2-[[2-(morpholin-4-yl)éthyl]sulfanyl]-1*H*-benzimidazole

fabomotizol

5-etoxi-2-[[2-(morfolin-4-il)etil]sulfanil]-1*H*-benzoimidazol



**facinclinum**  
facincline



*N*-[(3*S*)-1-azabicyclo[2.2.2]octan-3-yl]-1*H*-indazole-3-carboxamide

facincline

*N*-[(3*S*)-1-azabicyclo[2.2.2]octan-3-yl]-1*H*-indazole-3-carboxamide

faciniclina

*N*-[(3*S*)-1-azabicyclo[2.2.2]octan-3-il]-1*H*-indazol-3-carboxamida

**fiboflaponum**

fiboflapon



3-{3-(*tert*-butylsulfanyl)-1-[[4-(6-ethoxypyridin-3-yl)phényl]méthyl]-5-[(5-méthylpyridin-2-yl)méthoxy]-1*H*-indol-2-yl)-2,2-diméthylpropanoïque acid

fiboflapon

acide 3-{3-(*tert*-butylsulfanyl)-1-[[4-(6-éthoxypyridin-3-yl)phényl]méthyl]-5-[(5-méthylpyridin-2-yl)méthoxy]-1*H*-indol-2-yl)-2,2-diméthylpropanoïque

fiboflapon

ácido 3-{3-(*tert*-butilsulfanil)-1-[[4-(6-etoxipiridin-3-il)fenil]metil]-5-[(5-metilpiridin-2-il)metoxi]-1*H*-indol-2-yl)-2,2-dimetilpropanoico

**ficlatuzumabum #**

ficlatuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* HGF (hepatocyte growth factor, scatter factor, SF, hepatopoeitin A)], humanized monoclonal antibody;  
gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ4\*01 V124>L (114)) [8.8.11] (1-118) -*Homo sapiens*IGHG1\*03 (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV4-1\*01 (73.30%) -IGKJ2\*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC\*01 (108'-214')]; (227-227":230-230")-bisdisulfide dimer

ficlatuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* HGF (facteur de croissance de l'hépatocyte, facteur dispersant, SF, hépatopoïétine A)], anticorps monoclonal humanisé;  
chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ4\*01 V124>L (114)) [8.8.11] (1-118) -*Homo sapiens*IGHG1\*03 (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV4-1\*01 (73.30%) -IGKJ2\*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC\*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfure

## ficlitzumab

inmunoglobulina G1-kappa, anti-[HGF de *Homo sapiens* (factor de crecimiento del hepatocito, factor dispersante, SF, hepatopoyetina A)], anticuerpo monoclonal humanizado;  
cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ4\*01 V124>L (114)) [8.8.11] (1-118) -*Homo sapiens*IGHG1\*03 (119-448)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens*IGKV4-1\*01 (73.30%) -IGKJ2\*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC\*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQPGAE VKKPGTSVKL SCKASGYTFT TYWMHWVRQA PGQGLEWIGE 50  
INPTNGHTNY NQKFQGRATL TVDKSTSTAY MELSSLRSED TAVYYCARNY 100  
VGSIFDYWGQ GTLLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150  
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSSLGTQTYI 200  
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250  
TLMISRTPPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300  
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350  
TLPPSREEMT KNOVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD 400  
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNYHTQK SLSLSPGK 448

## Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAMSLGERVT LNCKASENVV SYVSWYQQKP GQSPKLLIYG 50  
ASNRESGVDP RFSGSGSATD FTLTISSVQA EDVADYHCGQ SYNYPYTFGQ 100  
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150  
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200  
LSSPVTKSFN RGEC 214

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro


Intra-H 22-96 145-201 262-322 368-426  
22"-96" 145"-201" 262"-322" 368"-426"  
Intra-L 23'-88' 134'-194'  
23'''-88''' 134'''-194'''  
Inter-H-L 221-214' 221"-214"  
Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
298, 298"galeteronum  
galeterone17-(1*H*-benzimidazol-1-yl)androsta-5,16-dien-3β-ol

## galétérone

17-(1*H*-benzimidazol-1-yl)androsta-5,16-dién-3β-ol

## galeterona



17-(1*H*-benzoimidazol-1-il)androsta-5,16-dien-3β-olC<sub>26</sub>H<sub>32</sub>N<sub>2</sub>Oganetesipibum  
ganetesipib5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1*H*-indol-5-yl)-2,4-dihydro-3*H*-1,2,4-triazol-3-one

## ganétespib

5-[2,4-dihydroxy-5-(propan-2-yl)phényl]-4-(1-méthyl-1*H*-indol-5-yl)-2,4-dihydro-3*H*-1,2,4-triazol-3-one

## ganetesipib

5-[2,4-dihidroxi-5-(propan-2-il)fenil]-4-(1-metil-1*H*-indol-5-il)-2,4-dihidro-3*H*-1,2,4-triazol-3-ona



**indatuximabum ravtansinum #**  
indatuximab ravtansine

immunoglobulin G4-kappa, anti-[*Homo sapiens* SDC1 (syndecan-1, CD138)], chimeric monoclonal antibody conjugated to maytansinoid DM4;  
gamma4 heavy chain (1-449) [*Mus musculus* VH (IGHV1-9\*01 - (IGHD)-IGHJ4\*01) [8.8.15] (1-122) -*Homo sapiens* IGHG4\*01 (123-449)], (136-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV10-94\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; (228-228'':231-231'')-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [*N*<sup>2</sup>-deacetyl-*N*<sup>2</sup>-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [*N*-succinimidyl 4-(2-pyridyldithio)butanoate]  
For the *ravtansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*"

indatuximab ravtansine

immunoglobuline G4-kappa, anti-[*Homo sapiens* SDC1 (syndecan-1, CD138)], anticorps monoclonal chimérique conjugué au maytansinoïde DM4;  
chaîne lourde gamma4 (1-449) [*Mus musculus* VH (IGHV1-9\*01 - (IGHD)-IGHJ4\*01) [8.8.15] (1-122) -*Homo sapiens* IGHG4\*01 (123-449)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-94\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM4 [*N*<sup>2</sup>-déacétyl-*N*<sup>2</sup>-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de *N*-succinimidyle]  
Pour la partie *ravtansine*, veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

indatuximab ravtansina

inmunoglobulina G4-kappa, anti-[SDC1 de *Homo sapiens* (sindecán-1, CD138)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM4;  
cadena pesada gamma4 (1-449) [*Mus musculus* VH (IGHV1-9\*01 - (IGHD)-IGHJ4\*01) [8.8.15] (1-122) -*Homo sapiens* IGHG4\*01 (123-449)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-94\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro; conjugado, en 3-4 grupos lisil por término medio con el maitansinoide DM4 [*N*<sup>2</sup>-desacetil-*N*<sup>2</sup>-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el espaciador SPDB reducible [4-(2-piridilditio)butanoato de *N*-succinimidilo]  
Para la fracción *ravtansina*, se ruega referirse al documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLQQSGSE	LMPGASVKI	SCKATGYTFS	NYWIEWVKQR	PGHGLEWIGE	50
ILPGTGRTIY	NEKFKGKATF	TADISSNTVQ	MQLSLSTSED	SAVYYCARRD	100
YYGNFYAMD	YWGQGTSTV	SSASTKGPSV	FPLAPCSRST	SESTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	200
KTYTCNVDPK	PSNTKVDKRV	ESKYGPPCP	CPAPEFLGGP	SVFLFPPKPK	250
DTLMISRTPE	VTCVVVDVQ	EDPEVQFNWY	VDGVEVHNAK	TKPREEQFNS	300
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKGL	PSSIEKTISK	AKGQPREPQV	350
YTLPPSQEEM	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTTPPVL	400
DSDGSFFLYS	RLTVDKSRWQ	EGNVFSCSVM	HEALHNHYTQ	KSLSLSLGK	449

## Light chain / Chaîne légère / Cadena ligera


DIQMTQSTSS	LSASLGDRVT	ISCSASQGIN	NYLNWYQQKP	DGTVELLIYY	50
TSTLQSGVPS	RFGSGSGGTD	YSLTISNLEP	EDIGTYICQQ	YSKLPRTFGG	100
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYSLSSSTLT	LSKADYEKKH	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	149-205	263-323	369-437
	22"-96"	149"-205"	263"-323"	369"-437"
Intra-L	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L	136-214'	136"-214"		
Inter-H-H	228-228"	231-231"		

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación


299, 299"

**iofolastatum** (<sup>123</sup>I)  
iofolastat (<sup>123</sup>I)*N*-{[(1*S*)-1-carboxy-5-{[(4-<sup>123</sup>I)iodophenyl)methyl]amino}pentyl]carbamoyl}-L-glutamic acidiofolastat (<sup>123</sup>I)acide *N*-{[(1*S*)-1-carboxy-5-{[(4-<sup>123</sup>I)iodophényl)méthyl]amino}pentyl]carbamoyl}-L-glutamiqueiofolastat (<sup>123</sup>I)ácido *N*-{[(1*S*)-1-carboxi-5-{[(4-<sup>123</sup>I)iodofenil)metil]amino}pentil]carbamoil}-L-glutámicoC<sub>19</sub>H<sub>26</sub><sup>123</sup>IN<sub>3</sub>O<sub>7</sub>**irdabisantum**  
irdabisant6-(4-{3-[(2*R*)-2-methylpyrrolidin-1-yl]propoxy}phenyl)pyridazin-3(2*H*)-one

## irdabisant

6-(4-{3-[(2*R*)-2-méthylpyrrolidin-1-yl]propoxy}phényl)pyridazin-3(2*H*)-one

## irdabisant

6-(4-{3-[(2*R*)-2-metilpirrolidin-1-il]propoxi}fenil)piridazin-3(2*H*)-onaC<sub>18</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub>

**ixekizumabum #**

ixekizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody;  
gamma4 heavy chain (1-445) [humanized VH (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens*IGHG4\*01 hinge S10>P (227), CH3 K130>del (120-445)], (133-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2D-29\*02 (89.00%) -IGKJ2\*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; (225-225'':228-228'')-bisdisulfide dimer

ixékizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé;  
chaîne lourde gamma4 (1-445) [VH humanisé (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens*IGHG4\*01 charnière S10>P (227), CH3 K130>del (120-445)], (133-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2D-29\*02 (89.00%) -IGKJ2\*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; dimère (225-225'':228-228'')-bisdisulfure

ixekizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado;  
cadena pesada gamma4 (1-445) [VH humanizada (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens*IGHG4\*01 bisagra S10>P (227), CH3 K130>del (120-445)], (133-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens*IGKV2D-29\*02 (89.00%) -IGKJ2\*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; dímero (225-225'':228-228'')-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYSFT DYHIHWVRQA PGQGLEWMGV 50
INPMYGTDDY NQRFKGRVTI TADESTSTAY MELSSLRSED TAVVYCARVD 100
YFTGTGVVWG QGTLVTVSSA STKGPSVFPFL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPVQLQSSG LYSLSVVTV PSSSLGTKTY 200
TCNVDRHKPSN TKVDKRVESK YGPPCPPCPA PEFLLGGPSVF LFPPKPKDKTL 250
MISRTPPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVELTLHQ DWLNGKEYKC KVSNGKLPSS IEKTIKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTTTPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMEHA LHNHYTQKSL SLSLG 445
```

## Light chain / Chaîne légère / Cadena ligera

```
DIVMTQTPLS LSVTPGQPAS ISCRSSRSLV HSRGNTYLHW YLQKPGQSPQ 50
LLIYKVSNNRF IGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHLP 100
FTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYFPREK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 260-320 366-424

22''-96'' 146''-202'' 260''-320'' 366''-424''

Intra-L 23'-93' 139'-199'

23'''-93''' 139'''-199'''

Inter-H-L 133-219' 133'-219''

Inter-H-H 225-225'' 228-228''

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

296, 296'

**ladarixinum**

ladarixin


4-[(2*R*)-1-oxo-1-(methanesulfonamido)propan-2-yl]phenyl trifluoromethanesulfonate

ladarixine

trifluorométhanesulfonate de 4-[(2*R*)-1-oxo-1-(méthanesulfonamido)propan-2-yl]phényle



ladarixina

trifluoromethanesulfonato de 4-[(2*R*)-1-oxo-1-(metanosulfonamido)propan-2-il]fenil $C_{11}H_{12}F_3NO_6S_2$ **lenomorelinum**  
lenomorelin $O^{3,26}$ -octanoylhuman appetite-regulating hormone (growth hormone-releasing peptide) precursor (protein M46)-(24-51)-peptide (ghrelin-28-C8)

lénomoréline


 $O^{3,26}$ -octanoylprécurseur de l'hormone humaine de régulation de l'appétit (précurseur du peptide de libération d'hormone de croissance, protéine M46)-(24-51)-peptide (ghréline-28-C8)

lenomorelina

 $O^{3,26}$ -octanoilprecursor de la hormona humana de regulación del apetito (precursor del péptido de liberación de hormona del crecimiento, proteína M46)-(24-51)-péptido (ghrelina-28-C8) $C_{149}H_{249}N_{47}O_{42}$ 

GSSFLSPEHQ RVQQRKESKK PPAKLQPR 28


Modified residue / Résidu modifié / Residuo modificado

**lesinuradum**  
lesinurad2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4*H*-1,2,4-triazol-3-yl]sulfanyl]acetic acid

lésinurad

acide 2-[[5-bromo-4-(4-cyclopropylnaphthalén-1-yl)-4*H*-1,2,4-triazol-3-yl]sulfanyl]acétique

lesinurad

ácido 2-[[5-bromo-4-(4-ciclopropilnaftalen-1-il)-4*H*-1,2,4-triazol-3-il]sulfanil]acético $C_{17}H_{14}BrN_3O_2S$ 

**lexibulium**

lexibulin


1-ethyl-3-[2-methoxy-4-(5-methyl-4-[[[(1S)-1-(pyridin-3-yl)butyl]amino]pyrimidin-2-yl)phenyl]urea

lexibuline

1-éthyl-3-[2-méthoxy-4-(5-méthyl-4-[[[(1S)-1-(pyridin-3-yl)butyl]amino]pyrimidin-2-yl)phényl]urée

lexibulina

1-etil-3-[2-metoxi-4-(5-metil-4-[[[(1S)-1-(piridin-3-il)butil]amino]pirimidin-2-il)fenil]urea

 $C_{24}H_{30}N_6O_2$ **lipegfilgrastimum #**

lipegfilgrastim

pegylated granulocyte colony stimulating factor;  
 $O^{3,133}$ -[ $N^6$ -( $N$ -{[ $\omega$ -methoxypoly(oxyethylene)]carbonyl}glycyl)- $\alpha$ -neuraminyl-(2 $\rightarrow$ 6)- $\alpha$ -D-galactopyranosyl]-L-methionyl-des-1-L-alanine-des-37-L-valine-des-38-L-serine-des-39-L-glutamic acid-human granulocyte colony-stimulating factor (G-CSF, pluripoietin)

lipegfilgrastim

facteur de stimulation de colonie de granulocytes humain pégylé;  
 $O^{3,133}$ -[ $N^6$ -( $N$ -{[ $\omega$ -méthoxypoly(oxyéthylène)]carbonyl}glycyl)- $\alpha$ -neuraminyl-(2 $\rightarrow$ 6)- $\alpha$ -D-galactopyranosyl]-L-méthionyl-dès-1-L-alanine-dès-37-L-valine-des-38-L-sérine-dès-39-L-acide glutamique-facteur de stimulation de colonie de granulocytes humain (G-CSF, pluripoïétine)

lipegfilgrastim

factor de estimulación de colonias de granulocitos humano pegilado;  
 $O^{3,133}$ -[ $N^6$ -( $N$ -{[ $\omega$ -metoxipoli(oxiétileno)]carbonil}glicil)- $\alpha$ -neuraminil-(2 $\rightarrow$ 6)- $\alpha$ -D-galactopiranosil]-L-metionil-des-1-L-alanina-des-37-L-valina-des-38-L-serine-des-39-L-ácido glutámico-factor de estimulación de colonias de granulocitos humanos (G-CSF, pluripoyetina)

 $C_{864}H_{1369}N_{225}O_{258}S_9 [C_2H_4O]_n$ 


```

                                M 0
TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL 50
GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAP ASAFQRRAGG 150
VLVASHLQSF LEVSYRVLRLH LAQP 174

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 36-42 64-74

Modified residue / Résidu modifié / Residuo modificado



**lorediplonum**


lorediplon

*N*-{2-fluoro-5-[3-(thiophene-2-carbonyl)pyrazolo[1,5-*a*]pyrimidin-7-yl]phenyl}-*N*-methylacetamide

lorédiplon

*N*-{2-fluoro-5-[3-(thiophène-2-carbonyl)pyrazolo[1,5-*a*]pyrimidin-7-yl]phényl}-*N*-méthylacétamide

lorediplón

*N*-{2-fluoro-5-[3-(tiofeno-2-carbonil)pirazolo[1,5-*a*]pirimidin-7-il]fenil}-*N*-metilacetamida $C_{20}H_{15}FN_4O_2S$ **lumacaftorum**

lumacaftor


3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido]-3-methylpyridin-2-yl}benzoic acid

lumacaftor

acide 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamido]-3-méthylpyridin-2-yl}benzoïque

lumacaftor

ácido 3-{6-[1-(2,2-difluoro-1,3-benzodioxol-5-il)ciclopropano-1-carboxamido]-3-metilpiridin-2-il}benzoico

 $C_{24}H_{18}F_2N_2O_5$ **lurbinectedinum**

lurbinectedin


(1'*R*,6*R*,6*aR*,7*R*,13*S*,14*S*,16*R*)-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-19-oxo-2',3',4',6,7,9',12,13,14,16-decahydro-6*aH*-spiro[7,13-azano-6,16-(epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquinolino[3,2-*b*][3]benzazocine-20,1'-pyrido[3,4-*b*]indol]-5-yl acetate

lurbinectédine

acétate de (1'*R*,6*R*,6*aR*,7*R*,13*S*,14*S*,16*R*)-8,14-dihydroxy-6',9-diméthoxy-4,10,23-triméthyl-19-oxo-2',3',4',6,7,9',12,13,14,16-décahydro-6*aH*-spiro[7,13-azano-6,16-(épihiopropanooxyméthano)[1,3]dioxolo[7,8]isoquinolino[3,2-*b*][3]benzazocine-20,1'-pyrido[3,4-*b*]indol]-5-yl

lurbinectedina

acetato de (1'*R*,6*R*,6*aR*,7*R*,13*S*,14*S*,16*R*)-8,14-dihidroxi-6',9-dimetoxi-4,10,23-trimetil-19-oxo-2',3',4',6,7,9',12,13,14,16-decahidro-16*H*-spiro[7,13-azano-6,16-(epitiopropanooximetano)[1,3]dioxolo[7,8]isoquinolino[3,2-*b*][3]benzazocina-20,1'-pirido[3,4-*b*]indol]-5-ilo

$C_{41}H_{44}N_4O_{10}S$ **melphalanum flufenamidum**


melphalan flufenamide

ethyl (2*S*)-2-[(2*S*)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanamido]-3-(4-fluorophenyl)propanoate

melphalan flufénamide

(2*S*)-2-[(2*S*)-2-amino-3-{4-[bis(2-chloroéthyl)amino]phényl}propanamido]-3-(4-fluorophényl)propanoate d'éthyle

melfalán flufenamida

(2*S*)-2-[(2*S*)-2-amino-3-{4-[bis(2-cloroetil)amino]fenil}propanamido]-3-(4-fluorofenil)propanoato de etilo $C_{24}H_{30}Cl_2FN_3O_3$ **mericitabinum**

mericitabine



(2'*R*)-2'-deoxy-2'-fluoro-2'-methyl-2',3'-bis-O-(2-methylpropanoyl)cytidine

méricitabine

3',5'-bis(2-méthylpropanoate) de (2'*R*)-2'-déoxy-2'-fluoro-2'-méthylcytidine

mericitabina

(2'*R*)-2'-desoxi-2'-fluoro-2'-metil-2',3'-bis-O-(2-metilpropanoil)citidina

**milciclibum**

milciclib



*N*,1,4,4-tetramethyl-8-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide

milciclib

*N*,1,4,4-tétraméthyl-8-[[4-(4-méthylpipérazin-1-yl)phényl]amino]-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide

milciclib

*N*,1,4,4-tetrametil-8-[[4-(4-metilpiperazin-1-il)fenil]amino]-4,5-dihidro-1*H*-pirazolo[4,3-*h*]quinazolina-3-carboxamida

**naldemedinum**

naldemedine



17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-*N*-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide

naldémédine

17-(cyclopropylméthyl)-6,7-didéhydro-4,5α-époxy-3,6,14-trihydroxy-*N*-[2-(3-phényl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide

naldemedina

17-(ciclopropilmetil)-6,7-didehidro-4,5α-epoxi-3,6,14-trihidroxi-*N*-[2-(3-fenil-1,2,4-oxadiazol-5-il)propan-2-il]morfinan-7-carboxamida



**naloxegolum**


naloxegol

4,5 $\alpha$ -epoxy-6 $\alpha$ -[(3,6,9,12,15,18,21-heptaoadocosan-1-yl)oxy]-17-(prop-2-en-1-yl)morphinan-3,14-diol

naloxégol

4,5 $\alpha$ -époxy-6 $\alpha$ -[(3,6,9,12,15,18,21-heptaoadocosan-1-yl)oxy]-17-(prop-2-én-1-yl)morphinane-3,14-diol

naloxegol

4,5 $\alpha$ -epoxi-6 $\alpha$ -[(3,6,9,12,15,18,21-heptaoadocosan-1-il)oxi]-17-(prop-2-en-1-il)morfinan-3,14-diolC<sub>34</sub>H<sub>53</sub>NO<sub>11</sub>**narnatumabum #**

narnatumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MST1R (macrophage stimulating 1 receptor, macrophage stimulating protein receptor, MSP receptor, c-met-related tyrosine kinase, protein-tyrosine kinase 8, PTK8, RON, p185-Ron, CD136)], *Homo sapiens* monoclonal antibody;  
gamma1 heavy chain (1-452) [*Homo sapiens* VH (IGHV3-7\*01 (95.90%) -(IGHD)-IGHJ6\*01 T127>I (119)) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (98.90%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; (231-231'':234-234'')-bisdisulfide dimer

narnatumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MST1R (récepteur 1 stimulant le macrophage, récepteur de la protéine stimulant le macrophage, récepteur de la MSP, tyrosine kinase apparentée à c-met, protéine-tyrosine kinase 8, PTK8, RON, p185-Ron, CD136)], *Homo sapiens* anticorps monoclonal;  
chaîne lourde gamma1 (1-452) [*Homo sapiens* VH (IGHV3-7\*01 (95.90%) -(IGHD)-IGHJ6\*01 T127>I (119)) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (98.90%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; dimère (231-231'':234-234'')-bisdisulfure


narnatumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MST1R (receptor 1 estimulante el macrófago, receptor de la proteína estimulante el macrófago, receptor de la MSP, tirosina kinasa relacionada con c-met, proteína-tirosina kinasa 8, PTK8, RON, p185-Ron, CD136)], *Homo sapiens* anticuerpo monoclonal;  
cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV3-7\*01 (95.90%) -(IGHD)-IGHJ6\*01 T127>I (119)) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (98.90%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuro



Heavy chain / Chaîne lourde / Cadena pesada			
EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	SYLMTWVRQA
IKQDGESEKYY	VDSVKGRFTI	SRDNAKNSLN	LQMNSLRAED
YSSGRHYGMD	VWGQGTIV	SSASTKGPSV	FPLAPSSKST
VKDYFPEPVT	VSWSNGALTS	GVHTFPAVLQ	SSGLYSLSV
QTYICNVNHK	PSNTKVDKRV	EPKSCDKTHT	CPPCPAPELL
KPKDTLMISR	TPEVTCVVVD	VSHPEDPEVKF	NWYVDGVEVH
YNSTYRVVSV	LTVLHQDWLN	GKEYCKKVS	NALPAPIEKT
PQVYTLPPSR	EEMTKNQVSL	TCLVKGFP	DIPEVEWESNG
PVLDSDGSFF	LYSKLTVDKS	RWQQGNVFC	SVMHEALHNN
GK			
Light chain / Chaîne légère / Cadena ligera			
EIVLTQSPAT	LSLSPGERAT	LSCRASQSVS	RYLAWYQKQP
ASNRATGIPA	RFSGSGSGTD	FTLTISSELP	EDFAVYYCQQ
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK
LSPVTKSFN	RGEC		
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro			
Intra-H	22-96	149-2105	266-326
	22"-96"	149"-205"	266"-326"
Intra-L	23'-88'	134'-194'	
	23"-88"	134"-194"	
Inter-H-L	225-214'	225"-214"	
Inter-H-H	231-231"	234-234"	
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación			
302, 302"			

navarixinum	2-hydroxy- <i>N,N</i> -dimethyl-3-[(2-[[[(1 <i>R</i> )-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-en-1-yl]amino]benzamide
navarixin	
navarixine	2-hydroxy- <i>N,N</i> -diméthyl-3-[(2-[[[(1 <i>R</i> )-1-(5-méthylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-én-1-yl]amino]benzamide
navarixina	2-hidroxi- <i>N,N</i> -dimetil-3-[(2-[[[(1 <i>R</i> )-1-(5-metilfuran-2-il)propil]amino]-3,4-dioxociclobut-1-en-1-il]amino]benzamida

C<sub>21</sub>H<sub>23</sub>N<sub>3</sub>O<sub>5</sub>



nelociguatum	methyl (4,6-diamino-2-{1-[(2-fluorophenyl)methyl]-1 <i>H</i> -pyrazolo[3,4- <i>b</i> ]pyridin-3-yl}pyrimidin-5-yl)carbamate
nelociguat	(4,6-diamino-2-{1-[(2-fluorophényl)méthyl]-1 <i>H</i> -pyrazolo[3,4- <i>b</i> ]pyridin-3-yl}pyrimidin-5-yl)carbamate de méthyle
nelociguat	(4,6-diamino-2-{1-[(2-fluorofenil)metil]-1 <i>H</i> -pirazolo[3,4- <i>b</i> ]piridin-3-il}pirimidin-5-il)carbamato de metilo



**nintedanibum**  
nintedanib



methyl (3*Z*)-3-[(4-[*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl)amino](phenyl)methylidene]-2-oxo-2,3-dihydro-1*H*-indole-6-carboxylate

nintédanib

(3*Z*)-3-[(4-[*N*-méthyl-2-(4-méthylpipérazin-1-yl)acétamido]phényl)amino](phényl)méthylidène]-2-oxo-2,3-dihydro-1*H*-indole-6-carboxylate de méthyle

nintedanib

(3*Z*)-3-[(4-[*N*-metil-2-(4-metilpiperazin-1-il)acetamido]fenil)amino](fenil)metiliden]-2-oxo-2,3-dihidro-1*H*-indol-6-carboxilato de metilo



**nivocasanum**  
nivocasan



(5*R*)-*N*-[(2*S*,3*S*)-2-(fluorométhyl)-2-hydroxy-5-oxooxolan-3-yl]-3-(isoquinolin-1-yl)-5-(propan-2-yl)-4,5-dihydro-1,2-oxazole-5-carboxamide

nivocasan

(5*R*)-*N*-[(2*S*,3*S*)-2-(fluorométhyl)-2-hydroxy-5-oxooxolan-3-yl]-3-(isoquinoléin-1-yl)-5-(propan-2-yl)-4,5-dihydro-1,2-oxazole-5-carboxamide

nivocasán

(5*R*)-*N*-[(2*S*,3*S*)-2-(fluorometil)-2-hidroxi-5-oxooxolan-3-il]-3-(isoquinolin-1-il)-5-(propan-2-il)-4,5-dihidro-1,2-oxazol-5-carboxamida





**oclacitinibum**


oclacitinib

*N*-methyl{*trans*-4-[methyl(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide

oclacitinib

*N*-méthyl[*trans*-4-(méthyl-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-ylamino)cyclohexyl]méthanesulfonamide

oclacitinib

*N*-metil{*trans*-4-[metil(7*H*-pirrolo[2,3-*d*]pirimidin-4-il)amino]ciclohexil}metanosulfonamida $C_{15}H_{23}N_5O_2S$ **olcorolimusum**

olcorolimus


(3*S*,6*S*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihydroxy-3-((1*R*)-1-[(1*S*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34<sup>a</sup>-icosahydro-11*H*-23,27-epoxypyrido[2,1-*c*][1,4]oxaazacyclohentacontine-1,11,28,29(31*H*)-tetrone

olcorolimus

(3*S*,6*S*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihydroxy-3-((1*R*)-1-[(1*S*,3*R*,4*R*)-4-hydroxy-3-méthoxycyclohexyl]propan-2-yl)-10,21-diméthoxy-6,8,12,14,20,26-hexaméthyl-3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34<sup>a</sup>-icosahydro-11*H*-23,27-époxy-pyrido[2,1-*c*][1,4]oxaazacyclohentacontine-1,11,28,29(31*H*)-tétrone

olcorolimús

(3*S*,6*S*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,27-dihidroxi-3-((1*R*)-1-[(1*S*,3*R*,4*R*)-4-hidroxi-3-metoxiciclohexil]propan-2-il)-10,21-dimetoxi-6,8,12,14,20,26-hexametil-3,4,5,6,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34<sup>a</sup>-icosahidro-11*H*-23,27-epoxipirido[2,1-*c*][1,4]oxaazaciclohentacontina-1,11,28,29(31*H*)-tetrona

 $C_{51}H_{81}NO_{12}$ 

**ordopidinum**

ordopidine

1-ethyl-4-[2-fluoro-3-(methanesulfonyl)phenyl]piperidine

ordopidine


1-éthyl-4-[2-fluoro-3-(méthylsulfonyl)phényl]pipéridine

ordopidina

1-etil-4-[2-fluoro-3-(metanosulfonyl)fenil]piperidina

C<sub>14</sub>H<sub>20</sub>FNO<sub>2</sub>S

871351-60-9

**ozoralizumabum #**

ozoralizumab

immunoglobulin single chain VH-VH'-VH, trivalent bispecific anti-[*Homo sapiens* TNF (tumor necrosis factor, TNF superfamily member 2, TNFSF2, TNFA, TNF-alpha)] VH and anti-[*Homo sapiens* ALB (albumin, human serum albumin, HAS)] VH', humanized *Lama glama* monoclonal antibody;

scVH-VH'-VH (1-363) [humanized VH (*Homo sapiens*IGHV3-74\*01 (88.80%) -(IGHD)-IGHJ1\*01 W118>R (105)) [8.8.8] (1-115) - 9-mer linker (tetraglycyl-seryl-triglycyl-seryl) (116-124) -humanized VH' (*Homo sapiens*IGHV3-23\*04 (89.60%) -(IGHD)-IGHJ1\*01 W118>S (229), G119>S (230) [8.8.8] (125-239) -9-mer linker (tetraglycyl-seryl-triglycyl-seryl) (240-248) -humanized VH (*Homo sapiens*IGHV3-74\*01 (88.80%) -(IGHD)-IGHJ1\*01 W118>R (353)(249-363)

ozoralizumab

immunoglobuline single chain VH-VH'-VH, trivalente bispécifique anti-[*Homo sapiens* TNF (facteur de nécrose tumorale, membre 2 de la superfamille du TNF, TNFSF2, TNFA, TNF-alpha)] VH et anti-[*Homo sapiens* ALB (albumine, sérum albumine humaine, SAH)] VH', anticorps monoclonal de *Lama glama* humanisé;

scVH-VH'-VH (1-363) [VH humanisé (*Homo sapiens*IGHV3-74\*01 (88.80%) -(IGHD)-IGHJ1\*01 W118>R (105)) [8.8.8] (1-115) -9-mer linker (tétraglycyl-séryl-triglycyl-séryl) (116-124) -VH' humanisé (*Homo sapiens*IGHV3-23\*04 (89.60%) -(IGHD)-IGHJ1\*01 W118>S (229), G119>S (230) [8.8.8] (125-239) -9-mer linker (tétraglycyl-séryl-triglycyl-séryl) (240-248) -VH humanisé (*Homo sapiens*IGHV3-74\*01 (88.80%) -(IGHD)-IGHJ1\*01 W118>R (353)(249-363)

ozoralizumab

inmunoglobulina de cadena sencilla VH-VH'-VH, trivalente biespecífica anti-[TNF de *Homo sapiens* (factor de necrosis tumoral, miembro 2 de la superfamilia del TNF, TNFSF2, TNFA, TNF-alpha)] VH y anti-[*Homo sapiens* ALB (albumina, albumina sérica humana SAH)] VH', anticuerpo monoclonal de *Lama glama* humanizado; scVH-VH'-VH (1-363) [VH humanizado (*Homo sapiens*IGHV3-74\*01 (88.80%) -(IGHD)-IGHJ1\*01 W118>R (105)) [8.8.8] (1-115) - conector nonúmero (tetraglicil-seril-triglicil-seril) (116-124) -VH' humanizado (*Homo sapiens*IGHV3-23\*04 (89.60%) -(IGHD)-IGHJ1\*01 W118>S (229), G119>S (230) [8.8.8] (125-239) - espaciador nonúmero (tetraglicil-seril-triglicil-seril) (240-248) -VH humanizado (*Homo sapiens*IGHV3-74\*01 (88.80%) -(IGHD)-IGHJ1\*01 W118>R (353)(249-363)

scVH-VH'-VH chain / Chaîne scVH-VH'-VH / Cadena scVH-VH'-VH  
 EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYWMYWVRQA PGKGLEWVSE 50  
 INTNGLITKY PDSVKGRFTI SRDNAKNTLY LQMNSLRPED TAVYYCARSP 100  
 SGFNRGQGTI VTVSSGGGGS GGGSEVQLVE SGGGLVQPGN SLRLSCAASG 150  
 FTFSSFGMSW VRQAPGKGLE WVSISGSGS DTLYADSVKG RFTISRDNAL 200  
 TTLYLQMSL RPEDTAVYYC TIGGSLRSRS QGTLVTVSSG GGGSGGGSEV 250  
 QLVEGGGLV QPGGSLRLSC AASGFTFSDY WMYWVRQAPG KGLEWVSEIN 300  
 TNGLITKYPD SVKGRFTISR DNAKNTLYLQ MNSLRPEDTA VYYCARSPSG 350  
 FNRGQGTIVT VSS 363

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 Intra-chain 22-96 146-220 270-34

**pateclizumabum #**  
 pateclizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* LTA (lymphotoxin alpha, TNFSF1, tumor necrosis factor superfamily member 1, LT)], humanized monoclonal antibody;  
 gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens*IGHV3-74\*01 (76.50%) -(IGHD)-IGHJ5\*01) [8.9.11] (1-118) -*Homo sapiens*IGHG1\*03 CH1 R120>K (215), CH3 K130>del (119-447)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-39\*01 (88.40%) -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC\*01 (108'-214')]; (227-227":230-230")-bisdisulfide dimer

patéclizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* LTA (lymphotoxine alpha, TNFSF1, membre 1 de la superfamille du facteur de nécrose tumorale, LT)], anticorps monoclonal humanisé;  
 chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens*IGHV3-74\*01 (76.50%) -(IGHD)-IGHJ5\*01) [8.9.11] (1-118) -*Homo sapiens*IGHG1\*03 CH1 R120>K (215), CH3 K130>del (119-447)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39\*01 (88.40%) -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC\*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfure

pateclizumab

inmunoglobulina G1-kappa, anti-[LTA de *Homo sapiens* (linfotóxina alfa, TNFSF1, miembro 1 de la superfamilia del factor de necrosis tumoral, LT)], anticuerpo monoclonal humanizado;  
 cadena pesada gamma1 (1-447) [VH humanizada (*Homo sapiens*IGHV3-74\*01 (76.50%) -(IGHD)-IGHJ5\*01) [8.9.11] (1-118) -*Homo sapiens*IGHG1\*03 CH1 R120>K (215), CH3 K130>del (119-447)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens*IGKV1-39\*01 (88.40%) -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC\*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

```

EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYVIHWVRQA PGKGLEWVG 50
NNPNAGTNY NEKFKGRFTI SSDKSKNTAY LQMNSLRAED TAVYYCSRPT 100
MLPWFAYWQO GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTWVSN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHS DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPPVL 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCVMH EALHNYTQK SLSLSFG 447

```

## Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS LSASVGDRVT ITCRASQAVS SAVAWYQQKP GKAPKLLIYS 50
ASHRYTGVPS RFGSGSGTD FTLTISSLQP EDFATYYCQE SYSTPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEC 214

```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 145-201 262-322 368-426  
 22"-96" 145"-201" 262"-322" 368"-426"  
 Intra-L 23'-88' 134'-194'  
 23'''-88''' 134'''-194'''  
 Inter-H-L 221-214' 221"-214"  
 Inter-H-H 227-227" 230-230"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

298, 298"

pegadricasum #  
pegadricase

pegylated Urate Oxidase from *Candida utilis*,  
 [198-threonine(S>T)]uricase (EC 1.7.3.3, urate oxidase) *Pichia jadinii* (Yeast) (*Candida utilis*) tetramer, 6-amino group of an average of 3 lysine residues, mostly in position 16, 19, and 85 of each monomer, are amidified with  $\alpha$ -(3-carboxypropanoyl)- $\omega$ -methoxypoly(oxyethylene)

## pégadricase

urate oxidase de *Candida utilis* pégylée,  
 [198-thréonine(S>T)]uricase (EC 1.7.3.3, urate oxydase) *Pichia jadinii* (levure) (*Candida utilis*), tétramère, la fonction amine en 6 de certaines lysines, en moyenne 3, principalement en positions 16, 19, et 85 de chaque monomère, sont amidifiées par le  $\alpha$ -(3-carboxypropanoyl)- $\omega$ -méthoxypoly(oxyéthylène)

## pegadricasa

urato oxidasa de *Candida utilis* pegilada,  
 [198-treonina(S>T)]uricasa (EC 1.7.3.3, urato oxidasa) *Pichia jadinii* (levadura) (*Candida utilis*), tetrámero, la función amina en 6 de ciertas lisinas, 3 por término medio, principalmente en las posiciones 16, 19, y 85 de cada monómero, está amidificada con  $\alpha$ -(3-carboxipropanoil)- $\omega$ -metoxipoli(oxielileno)


## Monomer / Monomère / Monómero

```

MSTTLSSSTY GKDNVKFLKV KKDPQNPKKQ EVMEATVTCL LEGGFDTSTY 50
EADNSSIVPT DTVKNITILVL AKTTEIWPIE RFAAKLATHF VEKYSVSHSV 100
SVKIVQDRWV KYAVDGGKPHD HSFIHEGGEK RITDLYYKRS GDYKLSSAIK 150
DLTVLKSTGS MFYGYNKCDF TTLQPTTDRI LSTDVDATWV WDNKKIGTVY 200
DIAKAADKGI FDNVYNQARE ITLTTFALFN SPSVQATMFN MATQILEKAC 250
SVYSVSYALP NKHYFLIDLK WKGLENDNEL FYPSPHPNGL IKCTVVRKEK 300
TKL 303

```

## Modified residues / Résidus modifiés / Residuos modificados



**peginterferonum lambda-1a #**

peginterferon lambda-1a

pegylated interferon lambda-1; pegylated interleukin 29;  
*N*-{3-[ $\alpha$ -methylpoly(oxyethylene)oxy]propyl}-L-methionyl[[171-serine]human interleukin-29 (IFN- $\lambda$ -1)-(7-181)-peptide}

péginterféron lambda-1a

interféron lambda-1 pégylé; interleukine-29 pégylée;  
*N*-{3-[ $\alpha$ -méthylpoly(oxyéthylène)oxy]propyl}-L-méthionyl[[171-sérine]interleukine-29 humaine (IFN- $\lambda$ -1)-(7-181)-peptide}

peginterferón lambda-1a

interferón lambda-1 pegilado; interleukina-29 pegilada;  
*N*-{3-[ $\alpha$ -metilpoli(oxietileno)oxi]propil}-L-metionil[[171-serina]interleukina-29 humana (IFN- $\lambda$ -1)-(7-181)-péptido}


C<sub>875</sub>H<sub>1408</sub>N<sub>254</sub>O<sub>251</sub>S<sub>5</sub> (C<sub>2</sub>H<sub>4</sub>O)<sub>n</sub>

```

MKPTT TKGCHIGRF KSLSPQELAS FKKARDALEE SLKLNWSCS 50
SPVFPGNWDL RLLQVRERP ALEAELALTL KVLEAAAGPA LEDVLDQPLH 100
TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV 150
TFNLFRLLTR DLKYVADGNL SLRTSTHPES T 181

```

Modified residue / Résidu modifié / Residuo modificado



Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 15-112 49-145

**pegnivacoginum**

pegnivacogin

a ribonucleic acid aptamer which binds Factor XIa;  
 ester of 2'-O-methyl-5'-O-phosphonoguanlyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→3')-thimidine with 6-[(2,6-bis{*N*-(ω-methoxypoly(oxyethylene)carbonyl)}-DL-lysyl)amino]hexan-1-ol

pégnavacogin

acide ribonucleique aptamère se liant au Factor XIa;  
ester de 2'-O-méthyl-5'-O-phosphonoguanilyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→3')-thimidine avec 6-[(2,6-bis{N-[ω-méthoxypoly(oxyéthylène)carbonyl]}-DL-lysyl)amino]hexan-1-ol


pegnavacogina

aptámero de ácido ribomucleico que se une a Factor XIa;  
éster of 2'-O-metil-5'-O-fosfonoguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-guanilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metilcitidilil-(3'→3')-timidina con 6-[(2,6-bis{N-[ω-metoxipoli(oxi-etileno)carbonyl]}-DL-lisil)amino]hexan-1-ol

C<sub>327</sub>H<sub>422</sub>F<sub>11</sub>N<sub>114</sub>O<sub>213</sub>P<sub>31</sub> (C<sub>2</sub>H<sub>4</sub>O)<sub>n</sub>

(3'-5')-R-pmG-mU-mG-mG-mA-dfC-dfU-mA-dfU-mA-dfC-dfC-mG-dfC-mG-dfU-mA-mA-dfU-mG-dfC-mU-G-mC-dfC-dfU-mC-mC-mA-mC<sup>3</sup>-3'dT  
Legend:  
dfU = 2'-deoxy-2'-fluoro ; m = 2'-O-methyl ; p (as prefix) = 5'-phosphate

R- =



**pimasertibum**  
pimasertib


*N*-[(2*S*)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]pyridine-4-carboxamide

pimasertib

*N*-[(2*S*)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophényl)amino]pyridine-4-carboxamide

pimasertib

*N*-[(2*S*)-2,3-dihidroxiopropil]-3-[(2-fluoro-4-iodofenil)amino]piridina-4-carboxamida

$C_{15}H_{15}FIN_3O_3$ **recoflavonum**


recoflavone

{[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4*H*-chromen-7-yl]oxy}acetic acid

récoflavone

acide {[2-(3,4-diméthoxyphényl)-5-méthoxy-4-oxo-4*H*-chromen-7-yl]oxy}acétique

recoflavona

ácido {[2-(3,4-dimetoxifenil)-5-metoxi-4-oxo-4*H*-cromen-7-il]oxi}acético $C_{20}H_{18}O_8$ **rucaparibum**


rucaparib

8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6*H*-pyrrolo[4,3,2-*ef*][2]benzazepin-6-one

rucaparib

8-fluoro-2-{4-[(méthylamino)méthyl]phényl}-1,3,4,5-tétrahydro-6*H*-pyrrolo[4,3,2-*ef*][2]benzazépin-6-one

rucaparib

8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahydro-6*H*-pirrolo[4,3,2-*ef*][2]benzazepin-6-ona $C_{19}H_{18}FN_3O$ **safotibantum**

safotibant


*N*-{[4-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl]methyl}-2-{[(4-methoxy-2,6-dimethylbenzenesulfonyl)(methyl)amino]ethoxy}-*N*-methylacetamide

safotibant

*N*-{[4-(4,5-dihydro-1*H*-imidazol-2-yl)phényl]méthyl}-2-{[(4-méthoxy-2,6-diméthylbenzènesulfonyl)(méthyl)amino]éthoxy}-*N*-méthylacétamide

safotibant

*N*-{[4-(4,5-dihidro-1*H*-imidazol-2-il)fenil]metil}-2-{2-[(4-metoksi-2,6-dimetilbencenosulfonil)(metil)amino]etoksi}-*N*-metilacetamido

C<sub>25</sub>H<sub>34</sub>N<sub>4</sub>O<sub>5</sub>S**selepressinum**

selepressin


vasopressin type 1a (V1a) receptor agonist;  
[2-*L*-phenylalanine, 3-*L*-isoleucine, 4-(6-oxo-*L*-lysine), 8-[5-*N*-(propan-2-yl)-*L*-ornithine]]human vasopressin

sélépressine

agoniste du récepteur de la vasopressine type 1a (V1a);  
[2-*L*-phénylalanine, 3-*L*-isoleucine, 4-(6-oxo-*L*-lysine), 8-[5-*N*-(propan-2-yl)-*L*-ornithine]]vasopressine humaine

selepresina

agonista del receptor de la vasopresina tipo 1<sup>a</sup> (V1a);  
[2-*L*-fenilalanina, 3-*L*-isoleucina, 4-(6-oxo-*L*-lisina), 8-[5-*N*-(propan-2-yl)-*L*-ornitina]]vasopresina humana

C<sub>46</sub>H<sub>73</sub>N<sub>13</sub>O<sub>11</sub>S<sub>2</sub>**sepantronii bromidum**

sepantronium bromide


1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-[(pyrazin-2-yl)methyl]-4,9-dihydro-1*H*-naphtho[2,3-*d*]imidazolium bromide

bromure de sépantronium

bromure de 1-(2-méthoxyéthyl)-2-méthyl-4,9-dioxo-3-[(pyrazin-2-yl)méthyl]-4,9-dihydro-1*H*-naphto[2,3-*d*]imidazolium

bromuro de sepantronio

bromuro de 2-metil-1-(2-metoxietil)-4,9-dioxo-3-[(pirazin-2-il)metil]-4,9-dihidro-1*H*-nafto[2,3-*d*]imidazolio

C<sub>20</sub>H<sub>19</sub>BrN<sub>4</sub>O<sub>3</sub>



**serelaxinum**

serelaxin

human relaxin 2 (relaxin H2)

sérélaïne

rélaïne 2 humaine (rélaïne H2)

serelaxina

relaxina 2 humana (relaxina H2)


 $C_{256}H_{408}N_{74}O_{74}S_8$ 

B chain / Chaîne B / Cadena B  
 DSWMEEVIKL CGRELVRAQI AICGMSTWS 29

A chain / Chaîne A / Cadena A  
 QLYSALANKC CHVGCTKRSL ARFC 24'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 10'-15' 11-11' 23-24'

Modified residue / Résidu modifié / Residuo modificado

**seridopidinum**

seridopidine


1-ethyl-4-[3-fluoro-5-(methanesulfonyl)phenyl]piperidine

sérídropidine

1-éthyl-4-[3-fluoro-5-(méthylsulfonyl)phényl]pipéridine

seridopidina

1-etil-4-[3-fluoro-5-(metanosulfonyl)fenil]piperidina

 $C_{14}H_{20}FNO_2S$ **simeprevirum**

simeprevir



(2*R*,3*aR*,10*Z*,11*aS*,12*aR*,14*aR*)-*N*-(cyclopropanesulfonyl)-2-({7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5-methyl-4,14-dioxo-2,3,3*a*,4,5,6,7,8,9,11*a*,12,13,14,14*a*-tetradecahydrocyclopenta[*c*]cyclopropa[*g*][1,6]diazacyclotetradecine-12*a*(1*H*)-carboxamide

siméprévir

(2*R*,3*aR*,10*Z*,11*aS*,12*aR*,14*aR*)-*N*-(cyclopropanesulfonyl)-2-({7-méthoxy-8-méthyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinoléin-4-yl}oxy)-5-méthyl-4,14-dioxo-2,3,3*a*,4,5,6,7,8,9,11*a*,12,13,14,14*a*-tétradécahydrocyclopenta[*c*]cyclopropa[*g*][1,6]diazacyclotétradécine-12*a*(1*H*)-carboxamide

simeprevir

(2*R*,3*aR*,10*Z*,11*aS*,12*aR*,14*aR*)-*N*-(ciclopropanosulfonyl)-2-({7-metoxi-8-metil-2-[4-(propan-2-il)-1,3-tiazol-2-il]quinolin-4-il}oxi)-5-metil-4,14-dioxo-2,3,3*a*,4,5,6,7,8,9,11*a*,12,13,14,14*a*-tetradecahidrociclopenta[*c*]ciclopropa[*g*][1,6]diazaciclótetradecina-12*a*(1*H*)-carboxamida

**siponimodum**

siponimod



1-({4-[(1*E*)-1-({[4-cyclohexyl-3-(trifluorométhyl)phényl]méthoxy}imino)éthyl]-2-éthylphényl)méthyl}azétidine-3-carboxylique

siponimod

acide 1-({4-[(1*E*)-1-({[4-cyclohexyl-3-(trifluorométhyl)phényl]méthoxy}imino)éthyl]-2-éthylphényl)méthyl}azétidine-3-carboxylique

siponimod

ácido 1-({4-[(1*E*)-1-({[4-ciclohexil-3-(trifluorometil)fenil]metoxi}imino)etil]-2-etilfenil}metil)azetidina-3-carboxílico

**sirukumabum #**

sirukumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL6 (interleukin 6, IL-6)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-7\*01 (87.80%) -IGHD)-IGHJ6\*01] [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-213')-disulfide with kappa light chain (1'-213') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (87.40%) -IGKJ4\*01) [5.3.9] (1'-107') -IGKC\*01 (107'-213')]; (228-231":228-231")-bisdisulfide dimer

sirukumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL6 (interleukine 6, IL-6)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma 1 (1-449) [*Homo sapiens* VH (IGHV3-7\*01 (87.80%) -IGHD)-IGHJ6\*01] [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-213')-disulfure avec la chaîne légère kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (87.40%) -IGKJ4\*01) [5.3.9] (1'-107') -IGKC\*01 (107'-213')]; dimère (228-228":231-231")-bisdisulfure

## sirukumab

inmunoglobulina G1-kappa, anti-[IL6 de *Homo sapiens* (interleukina 6, IL-6)], anticuerpo monoclonal de *Homo sapiens*;  
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV3-7\*01 (87.80%) -(IGHD)-IGHJ6\*01 [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-213')-disulfuro con la cadena ligera kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (87.40%) -IGKJ4\*01 [5.3.9] (1'-107') -IGKC\*01 (107'-213'))]; dímero (228-228":231-231")-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS PFAMSWVRQA PGKGLEWVAK 50
ISPGGSWYTY SDTDTVTGRTI SRDIAKNSLY LQMNSLRAED TAVYYCARQL 100
WGYALDIWG QGTTVTTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTWSW NSGALTSGVH TFPVAVLQSSG LYSLSVSVTV PSSSLGTQTY 200
ICNVNHHKPSN TKVDKKEVEK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LQDNLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPOV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449
```

## Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCASISVS YMYWYQQKPG QAPRLLIYDM 50
SNLASGIPAR FSGSGSGTDF TLTISSELEPE DFAVYYCMQW SGYPYTFGGG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWQVD 150
NALQSGNSQE SVTEQDSKDS TYSLSTLTLL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 146-202 263-323 369-427
        22"-96" 146"-202" 263"-323" 369"-427"
Intra-L 23'-87' 133'-193'
        23"'-87'" 133"'-193'"
Inter-H-L 222-213' 222"-213"
Inter-H-H 228-228" 231-231"
```

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

## solithromycinum

## solithromycin

(3aR,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl]butyl}-4-ethyl-7-fluoro-11-methoxy-3<sup>a</sup>,7,9,11,13,15-hexamethyl-10-[[trideoxy-(dimethylamino)-β-D-hexopyranosyl]oxy]octahydro-2H-oxacyclotetradecino[4,3-b][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetraone

## solithromycine


(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophényl)-1H-1,2,3-triazol-1-yl]butyl}-4-éthyl-7-fluoro-11-méthoxy-3a,7,9,11,13,15-hexaméthyl-10-[[3,4,6-tridéoxy-3-(diméthylamino)-β-D-xylo-hexopyranosyl]oxy]octahydro-2H-oxacyclotétradécino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tétrone

## solitromicina

(3aR,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminofenil)-1H-1,2,3-triazol-1-il]butil}-4-etil-7-fluoro-3<sup>a</sup>,7,9,11,13,15-hexametil-11-metoxi-10-[[tridesoxi-(dimetilamino)-β-D-hexopiranosil]oxi]octahidro-2H-oxaciclótetradecino[4,3-b][1,3]oxazol-2,6,8,14(1H,7H,9H)-tetraona

$C_{43}H_{65}FN_6O_{10}$ 

760981-83-7

**spriferminum #**  
spriferminL-methionyl[human fibroblast growth factor 18 (FGF-18, zFGF5)-  
(1-169)-peptide

sprifermine

L-méthionyl[facteur 18 de croissance du fibroblaste humain (FGF-18,  
zFGF5)-(1-169)-peptide]

esprifermina

L-metionil[factor 18 de crecimiento de fibroblastos humanos (FGF-  
18, zFGF5)-(1-169)-péptido] $C_{876}H_{1396}N_{258}O_{256}S_6$ 


EENVDFRIHV	ENQTRARDDV	SRKQLRLYLQ	YSRTSGKHIQ	VLGRRISARG	50
EDGDKYAQLL	VETDTFGSQV	RIKGEETEFY	LCMNRKGLV	GKPDGTSKEC	100
VFIEKVLENN	YTALMSAKYS	GWYVGFTKKG	RPRKGPKTRE	NQQDVHFMKR	150
YPKGQPELQK	PFKYTTVTK				169

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro  
82-100**suvorexantum**  
suvorexant[(7*R*)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-  
methyl-2-(2*H*-1,2,3-triazol-2-yl)phenyl]methanone

suvorexant

[(7*R*)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-méthyl-1,4-diazépan-1-yl][5-  
méthyl-2-(2*H*-1,2,3-triazol-2-yl)phényl]méthanone

suvorexant

[(7*R*)-4-(5-cloro-1,3-benzoxazol-2-il)-7-metil-1,4-diazepan-1-il][5-  
metil-2-(2*H*-1,2,3-triazol-2-il)fenil]metanona $C_{23}H_{23}ClN_6O_2$ 

**tabalumabum #**

tabalumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* TNFSF13B (tumor necrosis factor superfamily member 13B, BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, B cell activating factor, B lymphocyte stimulator, CD257)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-450) [*Homo sapiens* VH (IGHV4-34\*01 (100.00%) -(IGHD)-IGHJ4\*01) [8.7.17] (1-123) -IGHG4\*01 hinge S10>P (231) (124-450)], (137-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*05 (108'-214')]; (229-229":232-232")-bisdisulfide dimer

tabalumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* TNFSF13B (membre 13B de la superfamille du facteur de nécrose tumorale, BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, facteur d'activation des cellules B, stimulateur des lymphocytes B, CD257)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-450) [*Homo sapiens* VH (IGHV4-34\*01 (100.00%) -(IGHD)-IGHJ4\*01) [8.7.17] (1-123) -IGHG4\*01 charnière S10>P (231) (124-450)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*05 (108'-214')]; dimère (229-229":232-232")-bisdisulfure

tabalumab

inmunoglobulina G4-kappa, anti-[TNFSF13B de *Homo sapiens* (miembro 13B de la superfamilia del factor de necrosis tumoral, BAFF, THANK, TALL-1, TALL1, BLYS, BLyS, factor de activación de células B, estimulante de linfocitos B, CD257)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma4 (1-450) [VH de *Homo sapiens* (IGHV4-34\*01 (100.00%) -(IGHD)-IGHJ4\*01) [8.7.17] (1-123) -IGHG4\*01 bisagra S10>P (231) (124-450)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*05 (108'-214')]; dímero (229-229":232-232")-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLQQWGAG	LLKPSETLSL	TCAVYGGGSFS	GYYSWSWIRQP	PGKGLEWIGE	50
INHSGSTNYN	PSLKSRTVIS	VDTSKNQFSL	KLSSVTAADT	AVYYCARGYY	100
DILTGYYIYF	DYWGQGTIVT	VSSASTKGPS	VFPLAPCSRS	TSESTAALGC	150
LVKDYFPEPV	TVSWNSGALT	SGVHTFPAVL	QSSGLYSLSS	VVTVPSSSLG	200
TKTYTCNVDH	KPSNTKVDKR	VESKYGPPCP	PCPAPEFLGG	PSVFLFPKP	250
KDTLMISRTF	EVTCTVVDVS	QEDPEVQFNW	YVDGVEVHNA	KTKPREQFN	300
STYRVSVLT	VLHQDWLNGK	EYKCKVSNKG	LPSSIEKTIS	KAKGQPREPQ	350
VYTLPPSQEE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTPPV	400
LDSDGSFFLY	SRLTVDKSRW	QEGNVFSCSV	MHEALHNHYT	QKSLSLSLGK	450

## Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT	LSLSPGERAT	LSCRASQSVS	RYLAWYQQKP	GOAPRLLIYD	50
ASNRTATGIPA	RFSGSGSGTD	STLTISSLPE	EDFAVYYCQ	RSNWPRTFGQ	100
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYSLNLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-95	150-206	264-324	370-428
	22"-95"	150"-206"	264"-324"	370"-428"
Intra-L	23'-88'	134'-194'		
	23"-88"	134"-194"		
Inter-H-L	137-214'	137"-214"		
Inter-H-H	229-229"	232-232"		

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

300, 300"

**tefinostat**

tefinostat


cyclopentyl (2S)-2-[(4-[8-(hydroxyamino)-8-oxooctanamido]phenyl)methyl]amino]-2-phenylacetate

téfinostat

(2S)-2-[(4-[8-(hydroxyamino)-8-oxooctanamido]phényl)méthyl]amino]-2-phénylacétate de cyclopentyle

tefinostat

(2S)-2-[(4-[8-(hidroxiamino)-8-oxooctanamido]fenil)metil]amino]-2-fenilacetato de ciclopentilo

C<sub>28</sub>H<sub>37</sub>N<sub>3</sub>O<sub>5</sub>**tofacitinib**

tofacitinib


3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile

tofacitinib

3-[(3R,4R)-4-méthyl-3-[méthyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]pipéridin-1-yl]-3-oxopropanenitrile

tofacitinib

3-[(3R,4R)-4-metil-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]piperidin-1-il]-3-oxopropanonitrilo

C<sub>16</sub>H<sub>20</sub>N<sub>6</sub>O**trametinib**

trametinib


N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide

tramétinib

N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophényl)amino]-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phényl)acétamide

trametinib

N-(3-{3-ciclopil-5-[(2-fluoro-4-iodofenil)amino]-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidropirido[4,3-d]pirimidin-1(2H)-il}fenil)acetamida

C<sub>26</sub>H<sub>23</sub>FIN<sub>5</sub>O<sub>4</sub>

**upamostat**

upamostat


ethyl 4-[(2S)-3-{3-[(E)-N'-hydroxycarbamimidoyl]phenyl}-2-[2,3,5-tri(propan-2-yl)benzenesulfonamido]propanoyl]piperazine-1-carboxylate

upamostat

4-[(2S)-3-{3-[(E)-N'-hydroxycarbamimidoyl]phényl}-2-[2,3,5-tri(propan-2-yl)benzènesulfonamido]propanoyl]pipérazine-1-carboxylate d'éthyle

upamostat

4-[(2S)-3-{3-[(E)-N'-hidroxycarbamimidoil]fenil}-2-[2,3,5-tri(propan-2-il)benzenosulfonamido]propanoil]piperazina-1-carboxilato de etilo

C<sub>32</sub>H<sub>47</sub>N<sub>5</sub>O<sub>6</sub>S**vatelizumabum #**

vatelizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* ITGA2 (integrin alpha 2, CD49b, GPIa, subunit of the alpha2beta1 integrin (VLA-2, collagen receptor))], humanized monoclonal antibody; gamma4 heavy chain (1-446) [humanized VH (*Homo sapiens*IGHV4-59\*01 (79.40%) -(IGHD)-IGHJ6\*01) [8.7.13] (1-119) -*Homo sapiens*IGHG4\*01 (120-446)], (133-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens*IGKV6D-41\*01 (77.90%) -IGKJ1\*01) [5.3.9] (1'-106') -*Homo sapiens*IGKC\*01 (107'-213')]; (225-225'':228-228'')-bisdisulfide dimer

vatélizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* ITGA2 (intégrine alpha 2, CD49b, GPIa, sous-unité de l'intégrine alpha2bêta1 (VLA-2, récepteur du collagène))], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-446) [VH humanisé (*Homo sapiens*IGHV4-59\*01 (79.40%) -(IGHD)-IGHJ6\*01) [8.7.13] (1-119) -*Homo sapiens*IGHG4\*01 (120-446)], (133-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens*IGKV6D-41\*01 (77.90%) -IGKJ1\*01) [5.3.9] (1'-106') -*Homo sapiens*IGKC\*01 (107'-213')]; dimère (225-225'':228-228'')-bisdisulfure

vatelizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* ITGA2 (integrina alfa 2, CD49b, GPIa, subunidad de la integrina alfa2beta1 (VLA-2, receptor del colageno))], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-446) [VH humanizada (*Homo sapiens*IGHV4-59\*01 (79.40%) -(IGHD)-IGHJ6\*01) [8.7.13] (1-119) -*Homo sapiens*IGHG4\*01 (120-446)], (133-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizada (*Homo sapiens*IGKV6D-41\*01 (77.90%) -IGKJ1\*01) [5.3.9] (1'-106') -*Homo sapiens*IGKC\*01 (107'-213')]; dímero (225-225'':228-228'')-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLQESGPG	LVKPSSETLSL	TCTVSGFSLT	NYGIHWIRQP	PGKGLEWLG	50
IWARGFTNYN	SALMSRLTIS	KDNSKNQVSL	KLSSVTAADT	AVYYCARAND	100
GVYYAMDYWG	QGTLLTVSSA	STKGPSVFPL	APCSRSTSES	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TTPAVLQSSG	LYSLSSVVTV	PSSSLGKTGY	200
TCNVDHKPSN	TKVDKRVESK	YGPPCPSCPA	PEFLGGPSVF	LFPPKPKDTL	250
MISRTPEVTC	VVVDVQEDP	EVQFNWYVDG	VEVHNAKTKP	REEQFNSTYR	300
VVSVLTVLHQ	DWLNKKEYKC	KVSNKGLPSS	IEKTISKAKG	QPREPQVYTL	350
PPSQEEMTKN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	KTTTPVLDSD	400
GSFFLYSRLT	VDKSRWQEGN	VFSCSVMHEA	LHNHYTQKSL	SLSLKG	446

## Light chain / Chaîne légère / Cadena ligera

DFVMTQSPAF	LSVTPGEKVT	ITCSAQSSVN	YIHWHYQKPD	QAPKKLIYDT	50
SKLASGVPSP	FSGSGSGTDY	TFTISSLEAE	DAATYYCQOW	TNPLTFGQG	100
TKVEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD	150
NALQSGNSQE	SVTEQDSKDS	TYSLSTLTTL	SKADYEKKHV	YACEVTHQGL	200
SSPVTKSFNR	GEC				213

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-95	146-202	260-320	366-424
	22"-95"	146"-202"	260"-320"	366"-424"

Intra-L	23'-87'	133'-193'
	23'''-87'''	133'''-193'''

Inter-H-L	133-213'	133"-213"
Inter-H-H	225-225"	228-228"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

296, 296"

\* "INN for pharmaceutical substances: Names for radicals, groups & others" document available at / document disponible à / documento disponible en :

<http://www.who.int/medicines/services/inn/publication/en/index.html>

# Electronic structure available on Mednet: <http://mednet.who.int/>

# Structure électronique disponible sur Mednet: <http://mednet.who.int/>

# Estructura electrónica disponible en Mednet: <http://mednet.who.int/>



**AMENDMENTS TO PREVIOUS LISTS  
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES  
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Recommended International Non Proprietary Names (Rec. INN): List 6**  
(*Chronicle of the WHO, December 1959, Vol. 13, No. 12*)

p. 468      **mecamylaminum**  
mecamylamine      *replace the chemical name by the following*  
  
(1*RS*,2*SR*,4*SR*)-*N*,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine

**Denominations communes internationales recommandées (DCI Rec.): Liste 6**  
(*Chronique de l'OMS, Vol. 13, No. 12, décembre 1959*)


p. 488      **mecamylaminum**  
mécamylamine      *remplacer le nom chimique par le suivant*  
  
(1*RS*,2*SR*,4*SR*)-*N*,2,3,3-tétraméthylbicyclo[2.2.1]heptan-2-amine

**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 6**  
(*Crónica de la OMS, Vol. 13, No. 12, diciembre de 1959*)

p. 501      **mecamylaminum**  
mecamilamina      *sustitúyase el nombre químico por el siguiente*  
  
(1*RS*,2*SR*,4*SR*)-*N*,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina

**Recommended International Non Proprietary Names (Rec. INN): List 31**  
(*WHO Drug Information, Vol. 5, No. 3, 1991*)

p. 17      **beraprostum**  
beraprost      *replace the chemical name and the structure by the following ones*  
  
*rac*-4-[(1*R*,2*R*,3*aS*,8*bS*)-2-hydroxy-1-[(1*E*,3*S*,4*RS*)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3*a*,8*b*-tetrahydro-1*H*-cyclopenta[*b*][1]benzofuran-5-yl]butanoic acid




its epimer at C\* and their enantiomers  
son épimère en C\* et leurs énantiomères  
su epímero al C\* y sus enantiómeros

**Denominations communes internationales recommandées (DCI Rec.): Liste 31**  
*(Informations pharmaceutiques OMS, Vol. 5, No. 3, 1991)*

p. 18      **beraprostum**  
               béraprost

*remplacer le nom chimique et la structure par les suivants*

acide *rac*-4-[(1*R*,2*R*,3*aS*,8*bS*)-2-hydroxy-1-[(1*E*,3*S*,4*RS*)-3-hydroxy-4-méthyl-1-én-6-ynyl]-2,3,3*a*,8*b*-tétrahydro-1*H*-cyclopenta[*b*][1]benzofuran-5-yl]butanoïque




its epimer at C\* and their enantiomers  
 son épimère en C\* et leurs énantiomères  
 su epímero al C\* y sus enantiómeros

**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 31**  
*(Información farmacéutica OMS, Vol. 5, No. 3, 1991)*

p. 18      **beraprostum**  
               béraprost

*sustitúyase el nombre químico y la estructura por los siguientes*

ácido *rac*-4-[(1*R*,2*R*,3*aS*,8*bS*)-2-hidroxi-1-[(1*E*,3*S*,4*RS*)-3-hidroxi-4-metil-1-en-6-inil]-2,3,3*a*,8*b*-tetrahidro-1*H*-ciclopenta[*b*][1]benzofuran-5-il]butanoico



its epimer at C\* and their enantiomers  
 son épimère en C\* et leurs énantiomères  
 su epímero al C\* y sus enantiómeros

**Recommended International Non Proprietary Names (Rec. INN): List 62**  
**Denominations communes internationales recommandées (DCI Rec.): Liste 62**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62**  
*(WHO Drug Information, Vol. 23, No. 3, 2009)*

p. 250	<i>delete/supprimer/suprimáse</i>	<i>insert/insérer/insertese</i>
	<b>ingenoli mebutatum</b>	<b>ingenoli mebutas</b>

**Recommended International Non Proprietary Names (Rec. INN): List 63**  
**Denominations communes internationales recommandées (DCI Rec.): Liste 63**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63**  
**(WHO Drug Information, Vol. 24, No. 1, 2010)**

p. 69	<b>olodaterolum</b>	
	olodaterol	<i>replace the chemical name by the following</i>
	olodatérol	<i>remplacer le nom chimique par le suivant</i>
	olodaterol	<i>sustitúyase el nombre químico por el siguiente</i>
		6-hydroxy-8-[(1 <i>R</i> )-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i> )-one
		6-hydroxy-8-[(1 <i>R</i> )-1-hydroxy-2-[[1-(4-méthoxyphényl)-2-méthylpropan-2-yl]amino]éthyl]-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i> )-one
		6-hidroxi-8-[(1 <i>R</i> )-1-hidroxi-2-[[1-(4-metoxifenil)-2-metilpropan-2-il]amino]etil]-2 <i>H</i> -1,4-benzoxazin-3(4 <i>H</i> )-ona

**Recommended International Non Proprietary Names (Rec. INN): List 64**  
**Denominations communes internationales recommandées (DCI Rec.): Liste 64**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 64**  
**(WHO Drug Information, Vol. 24, No. 3, 2010)**

p. 264	<b>condoliasum #</b>	
	condoliase	<i>replace the structure by the following</i>
	condoliase	<i>remplacer la structure par la suivante</i>
	condoliasa	<i>sustitúyase la estructura por la siguiente</i>
		ATSNPAFDPK NLMQSEIYHF AQNNPLADFS SDKNSILTLS DKRSIMGNQS 50 LLWKWKGGSS FTLHKKLIVP TDKEASKAWG RSSTPVFSFW LYNEKPIDGY 100 LTIDFGEKLI STSEAQAGFK VKLDFTGWRA VGVSLNNDLE NREMTLNATN 150 TSSDGTQDSI GRS LGAKVDS IRFKAPS NVS QGEIYIDRIM FSVDDARYQW 200 SDYQVKTRLS EPEIQFHNVK PQLPVT PENL AAIDLIRQRL INEFVGG EKE 250 TNLALEENIS KLSDFDALN IHTLANGGTQ GRHLITDKQI IIYQENLNS 300 QDKQLFDNYV ILGNYTTLMF NISRAYVLEK DPTQKAQLKQ MYLLMTKHL 350 DQGFVKGSAL VTTHHWGYSS RWWYISTLLM SDALKEANLQ TQVYDSLWY 400 SREFKSSFDM KVSADSSDL D YFNTLSRQHL ALLLLEPDDQ KRINLVNTFS 450 HYITGALTQV PPGKDG LRP DGTAWRHEGN YPGYSFP AFK NASQLIYLR 500 DTPFSVGESG WNNLKKAMVS AWIYSNPEVG LPLAGRHPFN SPSLKSVAQG 550 YYWLAMSAKS SPDKTASIY LAISDKTQNE STAIFGETIT PASLPQGFYA 600 FNGGAFGIHR WQDKMVT LKA YNTNVWSSEI YNKDNRYGRY QSHGVAQIVS 650 NGSQLSQGYQ QEGWDWNRMQ GATTIHLPLK DLDSPKPHTL MQRGERGFSG 700 TSSLEGQYGM MAFDLIYPAN LERFDPNFTA KKSVLADNH LIFIGSNINS 750 SDKNKNVETT LFQHAITPTL NTLWINGQKI ENMPYQTTLQ QGDWLIDSNG 800 NGYLITQAEK VNVSRQHQS AENKNRQPT E GNFS SAWIDH STRPKDASYE 850 YMVFLDATPE KMGEMAQKFR ENNGLYQVLR KDKDVHII LD KLSNVTGYAF 900 YQPASIEDKW IKKVNKPAIV MTHRQKDTLI VSAVTPDLNM TRQKAATPVT 950 INVTINGKWQ SADKNSEVKY QVSGDNTELT FTSYFGIPQE IKLSPLP 997

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.